Delivery Methods for Treating Brain and Central Nervous System Disorders
The non-invasive ocular delivery of omega-3 fatty acids through the periorbital skin addresses the challenges of brain drug delivery by effectively transporting these compounds across the blood-brain barrier, offering a promising treatment for various brain and central nervous system diseases with reduced invasiveness and improved efficacy.
Patent Information
- Application Number
- JP2024527116
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-29
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for delivering therapeutic agents to the brain and central nervous system face challenges such as low efficiency across the blood-brain barrier, invasiveness, and high failure rates in clinical trials, particularly for neurodegenerative diseases like Alzheimer's and Parkinson's.
A non-invasive ocular delivery platform (NIODP) through the periorbital or eyelid skin is used to administer omega-3 fatty acids, including docosahexaenoic acid (DHA), which effectively delivers these compounds to the brain via the transocular/retinal transport pathway.
This method allows for safe and efficient delivery of therapeutic agents to the brain, reducing the therapeutic burden on patients and potentially treating a wide range of brain and central nervous system diseases, including neurodegenerative disorders, with lower doses required for therapeutic efficacy.
Smart Images

Figure 2024543050000001_ABST
Abstract
Description
[Technical field]
[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 63 / 283,121, filed November 24, 2021, and U.S. Provisional Application No. 63 / 401,918, filed August 29, 2022, the contents of which are incorporated by reference in their entireties herein.
[0002] Embodiments herein are directed to the delivery of compounds to the brain, central nervous system (CNS) and other parts of the body via non-invasive ocular delivery platforms (NIODPs) applied through the periorbital or eyelid skin of a patient to improve health and treat disease. Summary of the Invention
[0003] Provided herein are methods and compositions for the delivery of compounds comprising omega-3 fatty acids to the brain / CNS via periorbital or palpebral administration.Surprisingly, it has been found herein that omega-3 fatty acids comprising docosahexaenoic acid (DHA) can be effectively delivered to the brain / CNS via periorbital or palpebral administration.
[0004] In one aspect, provided herein is a method of promoting brain health and preventing or treating disease in a subject, the method comprising administering a topical pharmaceutical composition comprising an omega-3 fatty acid to the periorbital skin or eyelid of the subject's eye.
[0005] In some cases, the omega-3 fatty acid is isolated from fish tissue. In some cases, the omega-3 fatty acid is isolated from a plant source. In some cases, the omega-3 fatty acid comprises alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or any combination thereof. In some cases, the omega-3 fatty acid comprises DHA.
[0006] In some cases, the topical pharmaceutical composition comprises more than 50% DHA. In some cases, the topical pharmaceutical composition comprises more than 75% DHA. In some cases, the topical pharmaceutical composition comprises more than 90% DHA. In some cases, the topical pharmaceutical composition comprises more than 95% DHA. In some cases, the topical pharmaceutical composition comprises more than 99% DHA.
[0007] In some cases, the topical pharmaceutical composition includes petrolatum. In some cases, the topical pharmaceutical composition includes shea butter. In some cases, the topical pharmaceutical composition includes lanolin. In some cases, the topical pharmaceutical composition includes vitamin E. In some cases, the topical pharmaceutical composition includes less than 0.2% vitamin E.
[0008] In some cases, the omega-3 fatty acid is administered in an amount of about 0.1 mg to about 3000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 200 mg, or about 0.1 mg to about 100 mg. In some cases, the omega-3 fatty acid is administered in an amount of 5 to 10 mg per eye.
[0009] In some cases, the topical pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution. In some cases, the topical pharmaceutical composition further comprises an emollient, a moisturizer, a thickener, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof. In some cases, the topical pharmaceutical composition further comprises a preservative. In some cases, the topical pharmaceutical composition does not comprise a preservative.
[0010] In some cases, the topical pharmaceutical composition is administered with a rollerball bottle, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, eye pad, or fingertip.
[0011] In some cases, promoting brain health, preventing or treating disease in a subject includes treating or preventing addiction, arachnoid cysts, attention deficit hyperactivity disorder, autism, brain injury, brain tumors, catalepsy, encephalitis, epilepsy, meningitis, migraine headaches, multiple sclerosis, myelopathy, Tourette's syndrome, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
[0012] In some cases, the topical pharmaceutical composition is administered to a subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
[0013] In some cases, provided herein is a method for evaluating the safety profile of an article, comprising administering a topical composition comprising the article to the periorbital skin or eyelid of a subject's eye and measuring the concentration of the article in untreated ocular, brain or central nervous system tissue of the subject, where if the concentration of the article exceeds a threshold value, the administered article is determined to be acceptable for administration to the brain or central nervous system. In some cases, the untreated eye comprises retinal tissue.
[0014] In another aspect, provided herein is a method of delivering omega-3 fatty acids to the brain of a subject, comprising administering a topical pharmaceutical composition comprising an omega-3 fatty acid to the periorbital skin or eyelid of the subject's eye, wherein greater than 0.05% of the omega-3 fatty acid administered to the periorbital skin or eyelid of the subject is delivered to the brain of the subject.
[0015] In some cases, more than 0.1% of the omega-3 fatty acid administered to the subject's periorbital skin or eyelid is delivered to the subject's brain. In some cases, more than 0.5% of the omega-3 fatty acid administered to the subject's periorbital skin or eyelid is delivered to the subject's brain. In some cases, more than 1.0% of the omega-3 fatty acid administered to the subject's periorbital skin or eyelid is delivered to the subject's brain. In some cases, more than 4.0% of the omega-3 fatty acid administered to the subject's periorbital skin or eyelid is delivered to the subject's brain.
[0016] In some cases, the omega-3 fatty acid is isolated from fish tissue. In some cases, the omega-3 fatty acid is isolated from a plant source. In some cases, the omega-3 fatty acid comprises alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or any combination thereof. In some cases, the omega-3 fatty acid comprises DHA. In some cases, the topical pharmaceutical composition comprises more than 50% DHA. In some cases, the topical pharmaceutical composition comprises more than 75% DHA. In some cases, the topical pharmaceutical composition comprises more than 90% DHA. In some cases, the topical pharmaceutical composition comprises more than 95% DHA. In some cases, the topical pharmaceutical composition comprises more than 99% DHA. In some cases, the topical pharmaceutical composition comprises petrolatum. In some cases, the topical pharmaceutical composition comprises shea butter. In some cases, the topical pharmaceutical composition comprises lanolin. In some cases, the topical pharmaceutical composition comprises vitamin E. In some cases, the topical pharmaceutical composition comprises less than 0.2% vitamin E.
[0017] In some cases, the omega-3 fatty acid is administered in an amount of about 0.1 mg to about 3000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 200 mg, about 0.1 mg to about 100 mg, or about 0.1 mg to about 30 mg. In some cases, the omega-3 fatty acid is administered in an amount of 5 to 10 mg per eye.
[0018] In some cases, the topical pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution. In some cases, the topical pharmaceutical composition further comprises an emollient, a moisturizer, a thickener, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof. In some cases, the topical pharmaceutical composition further comprises a preservative. In some cases, the topical pharmaceutical composition does not comprise a preservative.
[0019] In some cases, the topical pharmaceutical composition is administered with a rollerball bottle, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, eye pad, or fingertip.
[0020] In some cases, delivery of the local pharmaceutical composition to the subject's brain prevents or treats a brain disease in the subject, in some cases the brain disease includes addiction, arachnoid cyst, attention deficit hyperactivity disorder, autism, brain injury, brain tumor, catalepsy, encephalitis, epilepsy, meningitis, migraine, multiple sclerosis, myelopathy, Tourette's syndrome, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
[0021] In some cases, the topical pharmaceutical composition is administered to a subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
[0022] In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 95% (w / w) of the composition. In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 50% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 5% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 50% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 95% (w / w) of the composition.
[0023] In some cases, the pharmaceutical composition further comprises vitamin E. In some cases, the pharmaceutical composition comprises vitamin E in an amount less than 0.3% (w / w) of the composition.
[0024] In another aspect, provided herein is a pharmaceutical composition formulated for topical administration to the periorbital area or eyelid, the pharmaceutical composition comprising an omega-3 fatty acid and one or more emollients.
[0025] In some cases, the omega-3 fatty acids are isolated from fish tissue. In some cases, the omega-3 fatty acids are isolated from plant sources. In some cases, the omega-3 fatty acids include alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or any combination thereof. In some cases, the omega-3 fatty acids include docosahexaenoic acid (DHA). In some cases, the pharmaceutical composition includes more than 50% DHA. In some cases, the pharmaceutical composition includes more than 75% DHA. In some cases, the pharmaceutical composition includes more than 90% DHA. In some cases, the pharmaceutical composition includes more than 95% DHA. In some cases, the pharmaceutical composition includes more than 99% DHA.
[0026] In some cases, the one or more emollients include petrolatum. In some cases, the one or more emollients include shea butter. In some cases, the one or more emollients include lanolin. In some cases, the pharmaceutical composition includes Vitamin E. In some cases, the pharmaceutical composition includes less than 0.2% Vitamin E.
[0027] In some cases, the pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution. In some cases, the pharmaceutical composition further comprises a moisturizer, a thickener, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof. In some cases, the pharmaceutical composition further comprises a preservative. In some cases, the pharmaceutical composition does not comprise a preservative.
[0028] In some cases, the pharmaceutical composition is administered using a bottle with a rollerball, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, eye pad, or fingertip.
[0029] In some cases, the pharmaceutical composition is administered to a subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
[0030] In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 95% (w / w) of the composition. In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 50% (w / w) of the composition. In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 5% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 5% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 50% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 95% (w / w) of the composition.
[0031] In some cases, the pharmaceutical composition further comprises vitamin E. In some cases, the pharmaceutical composition comprises vitamin E in an amount less than 0.3% (w / w) of the composition.
[0032] In some cases, the pharmaceutical composition further comprises more than 3000 μg of omega-3 fatty acid. In some cases, the pharmaceutical composition further comprises more than 5000 μg of omega-3 fatty acid. In some cases, the pharmaceutical composition further comprises more than 6000 μg of omega-3 fatty acid.
[0033] In another aspect, provided herein is a method of delivering omega-3 fatty acids to the brain of a subject, comprising administering a topical pharmaceutical composition comprising omega-3 fatty acids to the periorbital skin or eyelid of the subject's eye, wherein following administration, the concentration of omega-3 fatty acids in the brain of the subject is greater than 100 nmol per gram of tissue.
[0034] In some cases, following administration, the concentration of omega-3 fatty acids in the subject's brain exceeds 110 nmol per gram of tissue.
[0035] In some cases, the omega-3 fatty acid comprises DHA. In some cases, the topical pharmaceutical composition comprises more than 50% DHA. In some cases, the topical pharmaceutical composition comprises more than 75% DHA. In some cases, the topical pharmaceutical composition comprises more than 90% DHA. In some cases, the topical pharmaceutical composition comprises more than 95% DHA. In some cases, the topical pharmaceutical composition comprises more than 99% DHA.
[0036] In some cases, the topical pharmaceutical composition includes petrolatum. In some cases, the topical pharmaceutical composition includes shea butter. In some cases, the topical pharmaceutical composition includes lanolin. In some cases, the topical pharmaceutical composition includes vitamin E. In some cases, the topical pharmaceutical composition includes less than 0.2% vitamin E.
[0037] In some cases, the omega-3 fatty acid is administered in an amount of about 0.1 mg to about 3000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 200 mg, about 0.1 mg to about 100 mg, or about 0.1 mg to about 30 mg. In some cases, the omega-3 fatty acid is administered in an amount of 5 to 10 mg per eye.
[0038] In some cases, the topical pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution. In some cases, the topical pharmaceutical composition further comprises an emollient, a moisturizer, a thickener, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof. In some cases, the topical pharmaceutical composition further comprises a preservative. In some cases, the topical pharmaceutical composition does not contain a preservative. In some cases, the topical pharmaceutical composition is administered with a rollerball bottle, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, an eye pad, or a fingertip.
[0039] In some cases, delivery of the local pharmaceutical composition to the subject's brain prevents or treats a brain disease in the subject, in some cases the brain disease includes addiction, arachnoid cyst, attention deficit hyperactivity disorder, autism, brain injury, brain tumor, catalepsy, encephalitis, epilepsy, meningitis, migraine, multiple sclerosis, myelopathy, Tourette's syndrome, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
[0040] In some cases, the topical pharmaceutical composition is administered to a subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
[0041] In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 95% (w / w) of the composition. In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 50% (w / w) of the composition. In some cases, the pharmaceutical composition comprises one or more emollients in an amount less than 5% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 5% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 50% (w / w) of the composition. In some cases, the pharmaceutical composition comprises an omega-3 fatty acid in an amount of at least 95% (w / w) of the composition.
[0042] In some cases, the pharmaceutical composition further comprises vitamin E. In some cases, the pharmaceutical composition comprises vitamin E in an amount less than 0.3% (w / w) of the composition.
[0043] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]
[0044] [Figure 1] 1 illustrates a schematic diagram of the optic nerve in the brain.
[0045] [Diagram 2] 1 illustrates a model of the anterograde and retrograde transocular / retinal transport (TORT) pathways in the CNS.
[0046] [Diagram 3] 1 illustrates the anatomy of the periorbital region of the eye. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] Provided herein are methods and compositions for the delivery of compounds comprising omega-3 fatty acids via periocular or lid administration.Surprisingly, it has been found herein that omega-3 fatty acids, including docosahexaenoic acid (DHA), can be effectively delivered to the brain / CNS and the entire body via periocular or lid administration.
[0048] Drug delivery through the blood-brain barrier (BBB) remains a major challenge. Great efforts and various strategies have been utilized to deliver drugs and diagnostic agents to the brain. It is difficult to overcome various limitations, including low BBB crossing efficiency, invasiveness of intracerebral injection or intravenous (IV) administration, failure to translate from rodents to humans, and concerns about brain toxicity and long-term safety. Recently investigated is the nose-to-brain pathway, the mechanism of which is not yet clearly understood, with both migration across nerve fibers and migration via perivascular routes being hypothesized. Based on the findings in the systems and methods described herein, the mechanism of the nose-to-brain pathway involves migration across nerve fibers through the olfactory nervous system to the brain, then through the cerebrospinal fluid (CSF), and finally through the blood circulation. Unlike the rev-TORT pathway proposed in Figure 2 for the optic nervous system, there may be no direct material recirculation in the olfactory system because the left and right olfactory tracts do not cross. Furthermore, since a nose-to-brain route has been demonstrated in human studies with solution and particle formulations, the NIODP route may also be capable of delivering solutions and well-formulated particles to the brain. NIODP delivery appears to be much easier to implement, as a nose-to-brain dose must be deposited in the olfactory nerve area rather than the respiratory area, thus requiring specialized delivery devices.
[0049] In short, CNS drug delivery, efficacy and safety are major challenges, leading to significantly longer development times, longer post-development regulatory review, and often complete failure despite significant efforts. CNS drug attrition rates are extremely high. In major neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), which affect millions of people, the clinical failure rate of disease-modifying treatments has been 100%. Thus, new approaches in CNS drug development and delivery are urgently needed.
[0050] Non-invasive ocular delivery platforms (NIODPs) can open new routes for treating brain and systemic diseases. Delivery via the periorbital or eyelid skin may present a brain / CNS drug delivery route for treating the cause in addition to treating the symptoms of brain / CNS diseases. Drugs or any active ingredients that reach the retina via NIODPs or other routes may pass through the optic nerve via the transocular / retinal transport (TORT) pathway for optic nerve recirculation or clearance (Figure 2). NIODPs may deliver drugs and active ingredients to the brain / CNS via TORT.
[0051] FIG. 1 shows a schematic diagram of the optic nerve in the brain. The optic nerve connects the retina to the brain. The optic nerve begins at the optic nerve head (ONH), which is the confluence of the posterior retina, choroid, and sclera and the beginning of the cerebrospinal fluid (CSF) space of the eye. The optic nerve also contains the optic chiasm, an X-shaped structure formed by crossed and uncrossed axons or optic nerve fibers (OBF). The optic nerve also contains the lateral geniculate nucleus (LGN), a relay center in the thalamus where most of the neuronal synapses receive input from both eyes via crossed and uncrossed axons and transmit them to the visual cortex (VC).
[0052] After administration via NIODP or other routes to the retina, certain substances are readily accepted and can continue their migration along the optic nerve for distribution and absorption in the CNS (retina and brain) via the TORT pathway. For molecules and particles to remain in the CNS, they must meet certain requirements, such as having appropriate binding proteins, to pass through a complex sorting system. If these requirements are not met, the substance is identified as "waste" and can be rapidly removed by ATP-binding cassette efflux transporters, which are highly expressed in brain capillaries. Efflux transporters limit the uptake of certain molecules in the CNS and protect the CNS from exposure to circulating chemicals. The forward TORT pathway (solid black arrow, Figure 2) provides a rapid, unidirectional pathway that directs any "waste" molecules to be rapidly removed from the CNS to various nearby outlets, such as non-CNS tissues along the forward TORT pathway (including ocular tissues / muscles in untreated eyes, CSF, and / or blood for terminal clearance). On the other hand, as shown in Figure 2, after administration via NIODP or other routes to the retina, "permissible" molecules and particles can travel and circulate along the optic nerve in the CNS as follows: from the untreated or high-dose side of the retina to the ONH, to the contralateral side of the LGN by axonal transport via nasal retinal optic nerve fibers (crossed axons, 1a), and then to the contralateral ONH and retina by synaptic transmission via uncrossed axons (2a). Simultaneously, axonal transport via temporal retinal optic nerve fibers (uncrossed axons, 1b) to the LGN on the same side, and synaptic transmission via crossed axons (2b) to the ONH and retina on the contralateral side. · From both LGNs, follow the black arrows (3a and 3b) to both visual cortices (VC) by synaptic transmission in both LGNs.
[0053] As described in Figure 2, the proposed reverse TORT pathway (rev-TORT) may maintain a constant homeostatic system for rapid equilibration and constant balance of the concentration of molecules / particles identified as "acceptable", such as essential nutrients, between the retina and the optic nervous system. The rev-TORT may include from the retina and ONH of the contralateral eye to the original ONH and retina by following the red arrows rev-1a through rev-2a or rev-3a, rev-1b through rev-2b or rev-3b. The forward and reverse TORT pathways may be used for the delivery of brain therapeutics, especially essential nutrients.
[0054] After saturating the retinal tissue and remaining optic nervous system, if there is any excess "acceptable" material that cannot be completely absorbed by the CNS, it may spill over into the surrounding tissue / muscle along the TORT pathway for use or clearance.
[0055] A drug or formulation that can easily remain in the TORT pathway at high doses and be recirculated may indicate that the drug or formulation is safe for the brain and / or central nervous system. Therefore, the TORT pathway can be used to screen drugs or formulations that are safe for the brain or central nervous system, regardless of the delivery method (e.g., oral, intravenous, nose-to-brain, and / or brain). In some cases, a drug or formulation can be delivered via NIODP (either to the eyelid or periorbital skin) to evaluate its long-term safety profile. In some cases, a drug of the formulation can be delivered by intraocular injection (including subconjunctival, suprachoroidal, subretinal, and transscleral injection) to evaluate its long-term safety profile. Any delivery method that delivers a drug or formulation to the retina of one eye of a subject can be used. In some cases, a drug or formulation can be delivered to the eyelid or periorbital skin to evaluate its long-term safety profile in the brain and / or CNS. A drug or formulation that is readily accepted to remain in the TORT pathway and recirculate may be safe for the brain and / or CNS. A drug or formulation that is not readily accepted to remain in the TORT pathway and recirculate, but instead is rapidly removed from the administered retina, may not be safe for the brain and / or CNS. In some cases, a method for evaluating the safety profile of an article includes administering a topical composition comprising the article to the periorbital skin or eyelid of a subject's eye and measuring the concentration of the article in the subject's unadministered retinal, brain, or central nervous system tissue. In some cases, a method for evaluating the safety profile of an article includes intraocular injection (including subconjunctival, suprachoroidal, subretinal, and transscleral injection) of a formulation comprising the article into a subject's eye and measuring the concentration of the article in the subject's unadministered retinal, brain, or central nervous system tissue. If the concentration of the article is above a threshold value, the administered article may be determined to be acceptable for administration to the brain or central nervous system. If rapid equilibration and consistent balance of the article concentration between the administered and unadministered eyes of the retina is demonstrated, the administered article can be determined to be acceptable for administration to the brain or central nervous system.
[0056] Brain and central nervous system disorders Compared with current invasive intracerebral injection or intravenous (IV) administration for brain drugs, non-invasive NIODP delivery can reduce the therapeutic burden on patients, and lower doses of active ingredients may be required to deliver therapeutically appropriate amounts to both the central nervous system and the whole body. Disclosed embodiments are directed to the treatment of diseases of the central nervous system.
[0057] In some embodiments, the disease or disorder of the central nervous system comprises brain inflammation. In some embodiments, the brain inflammation is caused by a foreign body or a viral infection. In some embodiments, the disease or disorder of the central nervous system comprises an infectious disease. In some embodiments, the infectious disease is caused by a virus, a bacterium, a protozoan, a fungus, a prion, or a combination thereof. In some embodiments, the disease or disorder comprises a neurodegenerative disease or disorder. In some embodiments, the neurodegenerative disease or disorder comprises Alzheimer's disease, Huntington's disease, or Parkinson's disease, or a combination thereof. In some embodiments, the disease or disorder comprises addiction, arachnoid cyst, attention deficit hyperactivity disorder, autism, catalepsy, encephalitis, epilepsy, confinement extinction, meningitis, migraine, multiple sclerosis, myelopathy, or Tourette's syndrome, or a combination thereof. In some embodiments, the disease or disorder is caused by brain injury or a brain tumor.
[0058] Formulations applied in NIODP to treat diseases of the brain and CNS may include chlorpromazine, haloperidol, amisulpiride, levomepromazine, norclozapine, olanzapine, paliperidone, quetiapine, risperidone, sulpiride, triapride, ziprasidone, thioridazine, aripiprazole, clozapine, flupentixol, melperone, perphenazine, pimozide, raclopride, thioxanthene, trifluperazine hydrochloride, or ziprasidone, C-donepezil, dompezil, memantine, rivastigmine, or galantamine, efavirenz, atazanavir, emtricitabine, lamivudine, lopinovir, or tenovir, or combinations thereof.
[0059] Addiction is a disorder of the brain's reward system that is caused by transcriptional and epigenetic mechanisms and results over time from exposure to chronically high levels of addictive stimuli (e.g., morphine, cocaine, sex, gambling, etc.) In some embodiments, formulations can be delivered by NIODPs that correct malfunctioning transcriptional and epigenetic mechanisms and thus treat or minimize the severity of addiction.
[0060] In some embodiments, the formulation can be delivered by NIODP to treat arachnoid cysts. Arachnoid cysts are cerebrospinal fluid covered by arachnoid cells that can occur in the brain or spinal cord. They are congenital disorders and in some cases may not show symptoms. However, if there are large cysts, symptoms may include headaches, seizures, ataxia (lack of muscle control), hemiplegia, and several others. Macrocephaly and ADHD are common in children, while senile dementia, hydrocephalus (abnormal cerebrospinal fluid dynamics), and urinary incontinence are symptoms in elderly patients (over 65 years old).
[0061] In some cases, the formulation can be delivered by NIODP to treat attention deficit hyperactivity disorder (ADHD). ADHD is an organic disorder of the nervous system. ADHD, which can be debilitating in severe cases, has symptoms believed to be caused by structural and biochemical imbalances in the brain, particularly low levels of the neurotransmitters dopamine and norepinephrine, which are involved in the control and maintenance of attention and movement. Many people with ADHD continue to have symptoms well into adulthood. It is also worth noting that there is an increased risk of developing dementia with Lewy bodies, i.e. (DLB), and a direct genetic link between ADHD and Parkinson's disease, two progressive and serious neurological disorders whose symptoms often occur in people over the age of 65.
[0062] In some embodiments, the formulation can be delivered by NIODP to treat autism, a neurodevelopmental disorder characterized by restricted and repetitive patterns of behavior and persistent deficits in social interaction and communication.
[0063] In some embodiments, the formulations may be delivered by NIODP to treat brain injury or brain tumors. Tumors of the central nervous system make up approximately 2% of all cancers in the United States.
[0064] In some embodiments, the formulation may be delivered by NIODP to treat catalepsy. Catalepsy is a neurological disorder characterized by immobility and muscle rigidity along with decreased sensitivity to pain. Catalepsy is considered a symptom of serious diseases of the nervous system (e.g., Parkinson's disease, epilepsy, etc.) rather than a disease in itself. The duration of cataleptic attacks may range from minutes to weeks. Catalepsy often responds to tablet and IV forms of benzodiazepines (e.g., lorazepam).
[0065] In some embodiments, the formulation can be delivered by NIODP to treat encephalitis. Encephalitis is inflammation of the brain. It is usually caused by foreign body or viral infection. Symptoms of this disease include headache, neck pain, drowsiness, nausea and fever. When caused by West Nile virus, it can be fatal to humans, as well as birds and horses.
[0066] In some embodiments, the formulation may be delivered by NIODP to treat epilepsy. Epilepsy is an unpredictable, severe, potentially fatal disorder of the nervous system that is believed to be the result of defective electrical activity in the brain. Epileptic seizures result from abnormal, excessive, or hypersynchronous neuronal activity in the brain. Approximately 50 million people worldwide have epilepsy, with nearly 80% of epilepsy occurring in developing countries. Epilepsy becomes more common with age. The occurrence of new cases occurs most frequently in infants and the elderly. Epileptic seizures may occur in patients recovering as a result of brain surgery.
[0067] In some embodiments, the formulations can be delivered by NIODPs to treat infections of the CNS. A number of different pathogens (i.e., certain viruses, bacteria, protozoa, fungi, and prions) can cause infections that affect the brain or spinal cord.
[0068] In some embodiments, the formulations may be delivered by NIODP to treat locked-in syndrome, which usually results from a stroke that damages part of the brain stem, resulting in paralysis of most of the body and facial muscles, but remaining conscious and maintaining the ability to perform certain eye movements.
[0069] In some embodiments, the formulation may be delivered by NIODP to treat meningitis. Meningitis is an inflammation of the meninges (membranes) of the brain and spinal cord. It is most often caused by bacterial or viral infection. Fever, vomiting, and neck stiffness are all symptoms of meningitis.
[0070] In some embodiments, the formulations can be delivered by NIODPs to treat migraine, a chronic, often debilitating neurological disorder characterized by recurrent moderate to severe headaches, often associated with several autonomic nervous system symptoms.
[0071] In some embodiments, the formulation can be delivered by NIODP to treat multiple sclerosis (MS). MS is a chronic, inflammatory demyelinating disease, meaning that the myelin sheath of neurons is damaged. MS symptoms include visual and sensory problems, muscle weakness, generalized numbness and tingling, muscle spasms, incoordination, and depression. Patients with MS also report extreme fatigue and dizziness, tremors, and bladder leakage.
[0072] In some embodiments, the formulation can be delivered by NIODP to treat myelopathy.Myelopathy is damage to the spinal cord due to severe compression, which may be caused by trauma, congenital stenosis, degenerative disease or herniated disk.The spinal cord is a group of nerves housed inside the spine that runs almost its entire length.
[0073] In some embodiments, the formulation can be delivered by NIODP to treat Tourette's syndrome. Tourette's syndrome is a genetic neurological disorder. Early onset may be in childhood and is characterized by physical and verbal tics. Tourette's syndrome often also includes symptoms of both OCD and ADHD, showing a relationship between the three disorders. The exact cause of Tourette's syndrome is unknown, except for genetic factors.
[0074] In some embodiments, the formulation can be delivered by NIODP to treat or reduce symptoms associated with brain cancer. DHA has anti-inflammatory, anti-angiogenic, and analgesic properties, which can be beneficial to treat or reduce symptoms associated with brain cancer. In some cases, DHA can be delivered by NIODP to treat or reduce symptoms associated with brain cancer. DHA can be administered by NIODP as palliative / supportive care for patients undergoing cancer treatment, either primary brain tumor or brain tumor metastasis. DHA administered via NIODP can provide direct nutritional support to brain tissue, thus promoting the recovery of healthy tissue and countering the toxicity of cancer treatment. Thus, administration of DHA via NIODP to cancer patients may improve quality of life and shorten recovery time. For patients undergoing chemotherapy, DHA can be beneficial when administered during treatment and maintenance phase.
[0075] In some cases, DHA can be crosslinked with small molecule drugs to form DHA crosslinked small molecule drugs (DCSMDs) and delivered via NIODP to treat or alleviate symptoms associated with brain cancer. DCSMDs can aid in drug penetration via periorbital delivery to the brain. DCSMDs can increase drug retention in the brain, thereby reducing the frequency of administration. DHA or DCSMD drugs may or may not need to be released by enzymatic cleavage to become active drugs.
[0076] Neuroprotection and Neurodegenerative Disorders Formulations capable of delivering therapeutically relevant amounts of compounds to the central nervous system and blood are included, which is accomplished by application to the periorbital or eyelid skin. Disclosed embodiments are directed to the treatment of neurodegenerative disorders.
[0077] In some embodiments, DHA or any other omega-3 compound can be applied via NIODP for neuroprotection and to treat neurodegenerative diseases.Due to its tolerable safety profile and anti-inflammatory and neuroprotective mechanism of action, DHA can be a potential therapeutic agent for age-related neurodegenerative diseases.Research in animal models suggests that the normal nutritional intake of DHA above can modify the risk / course of some diseases of the brain.Epidemiological studies suggest that DHA / omega-3 fatty acid supplements can reduce the risk of Alzheimer's disease (AD) and Parkinson's disease (PD).
[0078] In some embodiments, the formulation can be delivered by NIODP to treat Alzheimer's disease. Alzheimer's disease is a neurodegenerative disease that typically occurs in people over 65 years of age. Approximately 24 million people worldwide have dementia, and 60% of these cases are due to Alzheimer's disease. The ultimate cause is unknown. The clinical sign of Alzheimer's is progressive cognitive decline. The formulation containing C-donepezil, donepezil, memantine, rivastigmine or galantamine can be delivered by NIODP to treat Alzheimer's disease.
[0079] In some embodiments, the formulation can be delivered by NIODP to treat Huntington's disease. Huntington's disease is an inherited degenerative neurological disorder. Degeneration of neuronal cells occurs throughout the brain, especially in the striatum. There is a gradual decline that leads to abnormal movements. Statistics show that Huntington's disease can affect 10 per 100,000 people of Western European descent.
[0080] In some embodiments, the formulation can be delivered by NIODP to treat Parkinson's disease. Parkinson's disease or PD is a progressive disease of the nervous system. It is caused by the death of dopamine-producing brain cells, which affects motor skills and speech. Symptoms can include bradykinesia (slow body movements), muscle rigidity and tremors. Behavior, thinking, sensory disorders, and sometimes coexisting skin condition seborrheic dermatitis are just a few of the many non-motor symptoms of PD. Parkinson's disease, attention deficit / hyperactivity disorder (ADHD) and bipolar disorder all seem to have some relationship with each other, because all three nervous system disorders involve lower than normal levels of the brain chemical dopamine (in the depression phase of ADHD, Parkinson's disease, and bipolar disorder) or too much dopamine in different areas of the brain. Hair growth disorder Formulations applied to the skin of the periorbital or eyelid (NIODP) can deliver therapeutically appropriate amounts of compounds to the systemic circulation to treat hair growth disorders. The disclosed embodiments are directed to hair growth disorders. DHA or any other omega-3 compounds can be applied via NIODP to treat hair growth disorders. Hair growth disorders can include androgenetic alopecia (male or female pattern hair loss), alopecia areata, scarring (scarring) alopecia, telogen effluvium, anagen effluvium, congenital hypotrichosis, or infection-related alopecia, such as tinea capitis and folliculitis. Omega-3 supplementation via delivery to the skin of the periorbital or eyelid can improve hair density and reduce the percentage of telogen and the proportion of miniaturized anagen hairs.
[0081] Autoimmune disorders Formulations applied to the periorbital or eyelid skin (NIODP) can deliver therapeutically relevant amounts of compounds to the systemic circulation to treat autoimmune disorders including Addison's disease, celiac disease, dermatomyositis, Graves' disease, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, pernicious anemia, Sjogren's syndrome, systemic lupus erythematosus, type I diabetes, Guillain-Barre syndrome, and scleroderma. Formulations delivered via the NIODP to treat autoimmune disorders can include anti-inflammatory drugs, corticosteroids, immunosuppressants, or omega-3 derivatives, or combinations thereof.
[0082] General condition Formulations applied to the periocular or eyelid skin (NIODP) may be capable of delivering therapeutically appropriate amounts of compounds to the systemic circulation to treat any type of condition affecting the body. In some embodiments, the formulations may be delivered by the NIODP to treat inflammatory soft tissue rheumatism, psoriatic arthritis, rheumatoid arthritis, and / or polyarthritis. Formulations delivered via the NIODP to treat arthritis may include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or disease-modifying antirheumatic drugs (DMARDs), or combinations thereof.
[0083] In some embodiments, the formulation can be delivered via NIODP to treat ankylosing spondylitis. The formulation delivered via NIODP to treat ankylosing spondylitis can include nonsteroidal anti-inflammatory drugs (NSAIDs), tofacitinib, etanercept, infliximab, adalimumab, golimumab, certolizumab, or secukinumab, or combinations thereof.
[0084] In some embodiments, the formulation can be delivered via NIODP to treat gout. The formulation delivered via NIODP to treat gout can include a nonsteroidal anti-inflammatory drug (NSAID), a corticosteroid, allopurinol, febuxostat, probenecid or pegloticase, or a combination thereof.
[0085] In some embodiments, the formulation can be delivered via NIODP to treat thrombophlebitis. The formulation delivered via NIODP to treat thrombophlebitis can include a nonsteroidal anti-inflammatory drug (NSAID), an anticoagulant, or a thrombolytic drug (alteplase), or a combination thereof.
[0086] In some embodiments, the formulation can be delivered via NIODP to treat vasculitis. The formulation delivered via NIODP to treat vasculitis can include corticosteroids, methotrexate, azathioprine, mycophenolic acid, cyclophosphamide, tocilizumab or rituximab, or a combination thereof.
[0087] In some embodiments, the formulation can be delivered via NIODP to treat renal fibrosis, chronic renal failure, and / or chronic liver disease. The formulation delivered via NIODP to treat liver disease can include vitamin E, pioglitazone, or ursodiol, or a combination thereof.
[0088] In some embodiments, the formulation may be delivered via a NIODP to treat pleurisy. The formulation delivered via a NIODP to treat pleurisy may include an NSAID.
[0089] In some embodiments, the formulation may be delivered via the NIODP to treat gastrointestinal disorders such as enteritis, irritable bowel syndrome, Crohn's disease, or diverticulitis. The formulation delivered via the NIODP to treat gastrointestinal disorders may include infliximab, adalimumab, golimumab, alosetron, eluxadoline, rifaximin, lubiprostone, linaclotide, ciprofloxacin, metronidazole, trimethoprim-sulfamethoxazole, or moxifloxacin, or a combination thereof.
[0090] In some embodiments, the formulation can be delivered via NIODP to treat endometriosis. The formulation delivered via NIODP to treat endometriosis can include elagolix or an aromatase inhibitor, or a combination thereof.
[0091] In some embodiments, the formulation may be delivered via the NIODP to treat a parasitic disease. The formulation delivered via the NIODP to treat a parasitic disease may include levamisole, niclosamide, praziquantel, albendazole, diethylcarbamazine, ivermectin, or thiabendazole, or a combination thereof.
[0092] In some embodiments, the formulation can be delivered via NIODP to treat cancer. The formulation delivered via NIODP to treat cancer can include chemotherapy, immunotherapy, or hormonal therapy, or a combination thereof. cardiovascular disease In some embodiments, the formulation can be delivered via NIODP to treat cardiovascular-related diseases, including deep vein thrombosis, atherosclerosis, pulmonary fibrosis, hypertension, hypertriglyceridemia, type 2 diabetes, obesity, and atherothrombosis. The formulation delivered via NIODP to treat cardiovascular diseases can include anticoagulants, including apixaban, dabigatran, edoxaban, heparin, rivaroxaban, or warfarin, or combinations thereof. The formulation delivered via NIODP to treat cardiovascular diseases can include antiplatelet agents and dual antiplatelet therapy (DAPTS), including aspirin, clopidogrel, dipyridamole, prasugrel, or ticagrelor, or combinations thereof. Formulations delivered via NIODP to treat cardiovascular disease may include angiotensin converting enzyme (ACE) inhibitors, including benazepril, captopril, enalapril, fosinopril, lisinopril, moxipril, perindopril, quinapril, ramipril, or trandolapril, or combinations thereof. Formulations delivered via NIODP to treat cardiovascular disease may include angiotensin II receptor blockers, including azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan, or combinations thereof. Formulations delivered via NIODP to treat cardiovascular disease may include beta blockers, including acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, or sotalol, or combinations thereof. Formulations delivered via the NIODP to treat cardiovascular disease may include statins, including atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin, or combinations thereof. Formulations delivered via the NIODP to treat cardiovascular disease may include diuretics or vasodilators.
[0093] respiratory disease In some embodiments, the formulations can be delivered via NIODP to treat respiratory diseases including allergies, asthma, pulmonary inflammation, pulmonary leukocyte infiltration, bronchial hyperresponsiveness, and allergic rhinitis. The formulations delivered via NIODP to treat respiratory diseases can include bronchodilators, nitric oxide, mucolytics, corticosteroids, leukotriene receptor antagonists, antihistamines, respiratory stimulants, pulmonary surfactants, or antivirals, or combinations thereof.
[0094] orthopedic disease In some embodiments, the formulations can be delivered via NIODP to treat orthopedic diseases, including bone and cartilage destruction, osteoporosis, and osteoarthritis. The formulations delivered via NIODP to treat orthopedic diseases can include alendronate, risedronate, ibandronate, zoledronic acid, romosozumab, or combinations thereof.
[0095] Skin conditions In some embodiments, the formulations can be delivered via the NIODP to treat skin conditions including atopic dermatitis, polymyositis, dermatomyositis, erythema nodosum, acne nodosum, pruritus nodosum, palmoplantar pustulosis, eczema, and psoriasis. The formulations delivered via the NIODP to treat skin conditions can include steroids, retinoids, biologics, methotrexate, or cyclosporine, or combinations thereof.
[0096] Omega-3 fatty acids The World Health Organization suggests that adults obtain 200 to 500 milligrams of omega-3 fatty acids, including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), per day for general health benefits. There are three main forms of omega-3 fatty acids: DHA and EPA, which are abundant in cold-water fish oils, and alpha-linolenic acid (ALA), which is commonly derived from plant sources.
[0097] It is well known that omega-3 fatty acid docosahexaenoic acid (DHA) plays important functional roles in brain and other systemic diseases, such as anti-inflammatory, anti-angiogenic, anti-apoptotic, and neuroprotective. Studies in animal models suggest that the above-mentioned normal nutritional intake of DHA can modify the risk / course of some diseases of the brain. Compared to other organs, DHA is highly enriched in the membrane phospholipids of brain and nervous tissues by daily dietary intake.
[0098] Approximately 4 mg of DHA per day is metabolized in the human brain, which undergoes a daily replenishment and recycling process during the regeneration of photoreceptor cells. Because the retina is an extension of the brain, the brain and retina are sometimes collectively referred to as the "brain". In the past, the pathway of DHA uptake from dietary nutrient absorption to the systemic blood circulation and then across the blood-brain barrier (BBB) to the brain has been widely debated. Essential fatty acids such as DHA, other omega-3 polyunsaturated fatty acids (n-3 PUFAs), and vitamin A have been proposed to cross the BBB via three potential mechanisms: passive diffusion, specialized transport proteins, and transcytosis.
[0099] In addition, omega-3 fatty acids, including DHA, can provide a local anesthetic effect. DHA has been shown to attenuate the nociceptive jaw opening reflex in rats and can be a therapeutic and complementary alternative for preventing acute trigeminal nociception or trigeminal neuralgia. DHA has been shown to demonstrate analgesic effects in postoperative pain after fracture in mice. DHA can promote the resolution of acute inflammation and inhibit inflammatory and neuropathic pain. DHA or its derivatives can be administered via NIODP to inhibit inflammatory and neuropathic pain. DHA or its derivatives can be administered via NIODP to treat, prevent, or reduce the severity of migraine headaches. Omega-3 fatty acids can be administered to the periorbital skin or eyelid skin to reduce triglyceride levels in adult patients with moderate or severe hypertriglyceridemia. Omega-3 fatty acids can be administered to the periorbital skin or eyelid skin to prevent and treat retinopathy of prematurity.
[0100] However, DHA is found in only a few dietary sources and is therefore the most difficult to ingest orally in sufficient amounts to benefit the eye.Therefore, improved methods of delivering DHA to treat diseases of the brain, central nervous system, and the rest of the body are needed.
[0101] In one aspect, provided herein is a method for delivering one or more omega-3 fatty acids to the brain, central nervous system, and / or to all parts of the body via administration to the skin of the periorbital or eyelid, and / or via systemic circulation. The omega-3 fatty acids can be derived from any suitable source. In some embodiments, the omega-3 fatty acids are isolated from fish tissue. The concentration of omega-3 in fish oil can be increased by ethylation. In some embodiments, the omega-3 fatty acids are isolated from a plant source. In some embodiments, the plant source of the omega-3 fatty acids is algae, seaweed, nori, spirulina, or chlorella. In some embodiments, the plant source of the omega-3 fatty acids is linseed oil.
[0102] In some embodiments, the omega-3 fatty acid is a C16-C24 omega-3 fatty acid, or a combination of C16-C24 omega-3 fatty acids. In some embodiments, the omega-3 fatty acid is a C18-C22 omega-3 fatty acid, or a combination of C18-C22 omega-3 fatty acids.
[0103] In some embodiments, the omega-3 fatty acid is hexadecatrienoic acid (HTA), alpha-linolenic acid (ALA), stearidonic acid (SDA), eicosatrienoic acid (ETE), eicosatetraenoic acid (ETA), eicosapentaenoic acid (EPA), heneicosapentaenoic acid (HPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), tetracosapentaenoic acid, tetracosahexaenoic acid, or any combination thereof. In some embodiments, the omega-3 fatty acid comprises tetraconsenoic acid, hexacosenoic acid, octacosenoic acid, or any combination thereof. In some embodiments, the omega-3 fatty acid comprises ALA, EPA, DHA, or any combination thereof. In some embodiments, the omega-3 fatty acid comprises DHA. In some embodiments, the omega-3 fatty acid comprises EPA. In some embodiments, the omega-3 fatty acid comprises ALA. In some embodiments, the omega-3 fatty acids include both DHA and EPA.
[0104] In some embodiments, the omega-3 fatty acid is in the form of omega-3 ethyl ester. Once in the skin, the omega-3 ethyl ester can be converted by esterase into omega-3 free acid, which can easily pass through the intercellular lipids of the stratum corneum and pores. In some embodiments, the omega-3 fatty acid comprises DHA ester. In some embodiments, the omega-3 fatty acid comprises EPA ester. In some embodiments, the omega-3 fatty acid comprises DHA ethyl ester. In some embodiments, the omega-3 fatty acid comprises EPA ethyl ester. In some embodiments, the omega-3 fatty acid comprises both DHA and EPA esters. In some embodiments, the omega-3 fatty acid comprises both DHA and EPA ethyl esters. In some embodiments, the omega-3 fatty acid comprises omega-3-carboxylic acid (free fatty acid composed mainly of EPA and DHA). In some embodiments, the omega-3 fatty acid comprises icosapentaethyl (ethyl ester of EPA).
[0105] In some embodiments, omega-3 fatty acid is in the form of omega-3 triglyceride.Natural fish oil mainly contains omega-3 fatty acid EPA and DHA in the form of omega-3 triglyceride.Omega-3 triglyceride has a molecular weight of approximately 900 Da.Once in the skin, omega-3 triglyceride can be converted into omega-3 free acid by lipase.Omega-3 triglyceride can also pass through intercellular lipids and capillary pores of the stratum corneum.
[0106] In some embodiments, the metabolites of omega-3 fatty acids can be administered to the periorbital or eyelid skin of the eye for substantial biodistribution to the eye, brain, and systemic tissues. In some embodiments, the omega-3 fatty acid metabolites can include leukotrienes or derivatives thereof. In some embodiments, the omega-3 fatty acid metabolites can include lipoxins or derivatives thereof. In some embodiments, the omega-3 fatty acid metabolites can include 5-series leukotrienes (LTB5, LTC5, LTD5, LTE5). In some embodiments, the omega-3 fatty acid metabolites can include prostanoids, such as prostacyclin, thromboxanes, or prostaglandins or derivatives thereof. In some embodiments, the omega-3 fatty acid metabolites can include 3-series prostanoids or prostaglandins. In some embodiments, the omega-3 fatty acid metabolites can include prostaglandin E3. In some embodiments, the omega-3 fatty acid metabolites can include prostaglandin I3. In some embodiments, the omega-3 fatty acid metabolites may include prostaglandin F3α. In some embodiments, the omega-3 fatty acid metabolites may include thromboxane A3. While EPA helps reduce chronic pain and inflammation anywhere in the body (e.g., for cardiovascular health or disease), DHA is optimal for the brain. To support brain health, the essential fatty acid supplement may have a DHA to EPA ratio of at least 4:1. In some embodiments, the essential fatty acid supplement may have a DHA to EPA ratio of 3:1. In some embodiments, the essential fatty acid supplement may have a DHA to EPA ratio of 2:1. In some embodiments, the essential fatty acid supplement may have a DHA to EPA ratio of 1:1. In some embodiments, the omega-3 fatty acid metabolites may include maresin or a derivative thereof. In some embodiments, the omega-3 fatty acid metabolites may include resolvin or a derivative thereof. In some embodiments, the omega-3 fatty acid metabolites may include protectin or a derivative thereof.
[0107] Combined with omega-3 fatty acids In treating various diseases or disorders, omega-3 fatty acid or its pharmaceutically acceptable ester or salt (DHA, EPA, etc.) can be combined with one or more additional therapeutic agents. Omega-3 fatty acid or its pharmaceutically acceptable ester or salt can be combined with one or more additional therapeutic agents, and this combination can be administered around the eyelid or topically to the subject. Omega-3 fatty acid or its pharmaceutically acceptable ester or salt can be combined with any of the therapeutic agents or active ingredients described herein. In some cases, omega-3 fatty acid is crosslinked with any of the therapeutic agents or active ingredients described herein.
[0108] In some embodiments, the patient being treated with the omega-3 fatty acid, or a pharma- ceutically acceptable ester or salt thereof, is further administered a VEGF antibody, or a functional fragment thereof.
[0109] In some embodiments, the patient being treated with the omega-3 fatty acid, or a pharma- ceutically acceptable ester or salt thereof, is further administered a tyrosine kinase inhibitor.
[0110] In some embodiments, the patient being treated with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof is further administered a steroidal anti-inflammatory agent, which in some embodiments is also selected from the group consisting of cortisone, prednisolone, methylprednisolone, raimcinolone, fluromethalone, medrysone, dexamethasone, lotprednol, hexatonide, betamethasone, paramethasone, diflorasone, fluocinonide, fluocinolone, fluticasone, and triamcinolone.
[0111] In some embodiments, the patient being treated with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof is further administered a nonsteroidal anti-inflammatory drug, in some embodiments, the nonsteroidal anti-inflammatory drug is selected from the group consisting of ketorolac, nepafenac, amfenac, aspirin, indomethacin, flurbiprofen, ibuprofen, rofecoxib, and celecoxib.
[0112] In some embodiments, the patient treated with omega-3 fatty acid or its pharma- ceutically acceptable ester or salt is further administered an immunosuppressant. In some embodiments, the immunosuppressant is selected from the group consisting of cyclosporine, liftegrast, methotrexate, azathioprine, inhibitors of the PI3K-AKT-mTOR signaling pathway (e.g., sirolimus, idelalisib, copanlisib, duvelisib, alpelisib, umbralisib, limpellisib, buparlisib, or BGB-10188), and agents that interfere with the activation and function of the complement pathway (e.g., POT-4, ARC1905).
[0113] In some embodiments, the patient is co-administered an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof and cyclosporine.
[0114] In some embodiments, the patient is co-administered with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof and liftegrast.
[0115] In some embodiments, the patient is co-administered an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof and methotrexate.
[0116] In some embodiments, the patient is co-administered with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof and azathioprine. In some embodiments, the patient is co-administered with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof and an inhibitor of the PI3K-AKT-mTOR signaling pathway (e.g., sirolimus, idelalisib, copanlisib, duvelisib, alpelisib, umbralisib, limpellisib, buparlisib, or BGB-10188).
[0117] In some embodiments, a nicotinic anticholinergic agent is further administered to the patient being treated with the omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof. In some embodiments, the nicotinic anticholinergic agent is selected from the group consisting of hexamethonium, decamethonium, and mecamyrin.
[0118] In some embodiments, the patient being treated with the omega-3 fatty acid, or a pharma- ceutically acceptable ester or salt thereof, is further administered thalidomide.
[0119] In some embodiments, the patient treated with omega-3 fatty acid or its pharma- ceutically acceptable ester or salt is further administered a prostaglandin receptor antagonist.In some embodiments, the antagonist blocks multiple prostaglandin receptors.In some embodiments, the antagonist is AGN 211377 and AGN 225660.
[0120] In some embodiments, a neuroprotective agent is further administered to the patient being treated with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof. In some embodiments, the neuroprotective agent is an α2-adrenergic receptor agonist (e.g., brimonidine), an NMDA antagonist (e.g., memantine), an AMPA antagonist, a Ca 2+ blockers, sigma-Irs receptor agonists, pentazocine, endothelin receptor antagonists, kinin antagonists and anti-TNFα antibodies.
[0121] In some embodiments, the patient being treated with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof may also be administered a neurotrophic / neuroregenerative agent (e.g., ciliary neurotrophic factor, nerve growth factor, brain-derived neurotrophic factor, glial-derived neurotrophic factor I, neurotrophic factor 3), heat shock protein, JNK inhibitor, synthetic bile acid (e.g., UDCA, TUDCA), progesterone, dopamine agonist, neurotrophic factor, caspase inhibitor, acetyl-L-carnitine, acetylcholinesterase inhibitor, citicoline, acetylcysteine, retinoids, or the like. In addition, agents that interfere with the activation and function of the complement pathway, such as vinpocetine, ...
[0122] In some embodiments, the patient treated with omega-3 fatty acid or its pharma- ceutically acceptable ester or salt is further administered an RNA interference molecule. In some embodiments, the RNA interference molecule can be siRNA, miRNA, or shRNA. In some embodiments, the RNA interference molecule is complementary to a gene sequence that codes for a protein. In some embodiments, the RNA interference molecule has a sequence that is at least partially complementary to a gene sequence that codes for a protein. In some embodiments, the presence of the RNA interference molecule results in silencing of the gene that codes for the protein. In some embodiments, the protein is a receptor. In some embodiments, a combination of at least two RNA interference molecules is further administered to the patient. In some embodiments, the combination of at least two RNA interference molecules silences at least two protein-coding genes. In some embodiments, the protein is an enzyme. In some embodiments, the protein is selected from the group of VEGF, PDGF, bFGF, SDF-1, HIF-1, PIGF, GLUT-1, claudin cell adhesion molecules, HMBG-1, HuR, Ets1, GSK3β, RTP801, caspase 2-, 3-, 7-, PGC-1, ICAM1, t-PA, SNAI1, TBK1, ARMS2, TERT, ASK-1, and Nrf-2.
[0123] In some embodiments, the RNA interference molecule is a single-stranded RNA. In some embodiments, the RNA interference molecule is a double-stranded RNA. In some embodiments, the RNA interference molecule is about 10 nucleotides to about 200 nucleotides in length. In some embodiments, the chain length of the RNA interference molecule is about 10 nucleotides to about 20 nucleotides, about 10 nucleotides to about 30 nucleotides, about 10 nucleotides to about 40 nucleotides, about 10 nucleotides to about 50 nucleotides, about 10 nucleotides to about 60 nucleotides, about 10 nucleotides to about 70 nucleotides, about 10 nucleotides to about 80 nucleotides, about 10 nucleotides to about 90 nucleotides, about 10 nucleotides to about 100 nucleotides, about 10 nucleotides to about 200 nucleotides, about 20 nucleotides to about 30 nucleotides, about 20 nucleotides to about 40 nucleotides, about 20 nucleotides to about 50 nucleotides, about 20 nucleotides to about 60 nucleotides, about 20 nucleotides to about 70 nucleotides, about 20 nucleotides to about 80 nucleotides, about 20 nucleotides to about 90 nucleotides, about 20 nucleotides to about 100 nucleotides, about 20 nucleotides to about 200 nucleotides, about 30 nucleotides to about 40 nucleotides, about 30 nucleotides to about 50 nucleotides, about 30 nucleotides to about 60 nucleotides, about 30 nucleotides to about 70 nucleotides, about 30 nucleotides to about 80 nucleotides, about 30 nucleotides to about 90 nucleotides, about 30 nucleotides to about 100 nucleotides, about 30 nucleotides to about 200 nucleotides, about 40 nucleotides to about 50 nucleotides, about 40 nucleotides to about 60 nucleotides, about 40 nucleotides to about 70 nucleotides, about 40 nucleotides to about 80 nucleotides, about 40 nucleotides to about 90 nucleotides, about 40 nucleotides to about 100 nucleotides, about 40 nucleotides to about 200 nucleotides, about 50 nucleotides to about 60 nucleotides, about 50 nucleotides to about 70 nucleotides, about 50 nucleotides to about 80 nucleotides, about 50 nucleotides to about 90 nucleotides, about 50 nucleotides to about 100 nucleotides, about 50 nucleotides to about 200 nucleotides, about 60 nucleotides to about 70 nucleotides, about 60 nucleotides to about 80 nucleotides, about 60 nucleotides to about 90 nucleotides,The length is about 60 nucleotides to about 100 nucleotides, about 60 nucleotides to about 200 nucleotides, about 70 nucleotides to about 80 nucleotides, about 70 nucleotides to about 90 nucleotides, about 70 nucleotides to about 100 nucleotides, about 70 nucleotides to about 200 nucleotides, about 80 nucleotides to about 90 nucleotides, about 80 nucleotides to about 100 nucleotides, about 80 nucleotides to about 200 nucleotides, about 90 nucleotides to about 100 nucleotides, about 90 nucleotides to about 200 nucleotides, or about 100 nucleotides to about 200 nucleotides. In some embodiments, the length of the RNA interference molecule is about 10 nucleotides, about 20 nucleotides, about 30 nucleotides, about 40 nucleotides, about 50 nucleotides, about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 100 nucleotides, or about 200 nucleotides. In some embodiments, the length of the RNA interference molecule is at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides. In some embodiments, the length of the RNA interference molecule is at most about 20, 30, 40, 50, 60, 70, 80, 90, 100, or 200 nucleotides.
[0124] In some embodiments, the RNA interference molecule may prevent the expression of a VEGF receptor or attenuate the biosynthesis of VEGF and its various isoforms.
[0125] In some embodiments, the patient being treated with the omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof is further administered an RNA interference molecule selected from the group that reduces or eliminates receptor expression or reduces the biosynthesis of PDGF, bFGF, SDF-1, HIF-1, PIGF, GLUT-1, claudin cell adhesion molecules, HMBG-1, HuR, Ets1, GSK3β, RTP801, caspase 2-, 3-, 7-, PGC-1, ICAM1, t-PA, SNAI1, TBK1, SRPK1, C1Q, HtrA1, ARMS2, TERT, ASK-1, and Nrf-2.
[0126] In some embodiments, the patient being treated with omega-3 fatty acids or pharma- ceutically acceptable esters or salts thereof is further administered an antioxidant, which in some embodiments is selected from the group consisting of β-carotene, lutein, zeaxanthin, riboflavin, niacin, and polyunsaturated fatty acids such as docosohexanoic acid (DHA), eicosapentaenoic acid (EPA), vitamin B3, vitamin B6, vitamin B9, vitamin B10, vitamin B12, vitamin B13, vitamin B14, vitamin B15, vitamin B16, vitamin B17, vitamin B18, vitamin B20, vitamin B210, vitamin B220, vitamin B23, vitamin B24, vitamin B25, vitamin B36, vitamin B37, vitamin B48, vitamin B49, vitamin B50, vitamin B51, vitamin B52, vitamin B53, vitamin B54, vitamin B55, vitamin B56, vitamin B57, vitamin B58, vitamin B60, vitamin B61, vitamin B62, vitamin B63, vitamin B64, vitamin B65, vitamin B66, vitamin B67, vitamin B68, vitamin B69, vitamin B70, vitamin B71, vitamin B72, vitamin B73, vitamin B74, vitamin B75, vitamin B76, vitamin B77, vitamin B78, vitamin B79, vitamin B90, vitamin B91, vitamin B92, vitamin B93, vitamin B94, vitamin B95, vitamin B96, vitamin B97, vitamin B98, vitamin B99, vitamin B109, vitamin B102, vitamin B103, vitamin B104, vitamin B105, vitamin B106, vitamin B107, vitamin B108, vitamin B109, vitamin B109, vitamin B110, vitamin B111, vitamin B112, vitamin B113, vitamin B114, vitamin B115, vitamin B116, vitamin 12 , vitamin C, vitamin E, CoQ10, ghrelin, alpha-lipoic acid, resveratrol, flavonoids, Ginkgo Bilbao extract, ICAPS R®, OFTAN MACULA®, and epigallocatechin-3-gallate.
[0127] In some embodiments, a therapeutic antibody is further administered to a patient treated with omega-3 fatty acid or its pharmaceutically acceptable ester or salt. In some embodiments, the therapeutic antibody is an antibody that interferes with the activation and function of the complement pathway. In some embodiments, the administration of omega-3 fatty acid or its pharmaceutically acceptable ester or salt reduces the amount of therapeutic antibody that would otherwise need to be administered to produce the intended therapeutic effect. In some embodiments, the reduction in the amount of therapeutic antibody is manifested as a lower dose of the therapeutic antibody, or preferably fewer or less frequent injections of the therapeutic antibody.
[0128] In some embodiments, a patient being treated with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof is further administered a therapeutic epigenetic modulator of acylation, deacylation, methylation, or demethylation of histone proteins. In some embodiments, the omega-3 fatty acid or a pharma-ceutically acceptable ester or salt thereof and the additional therapeutic agent are formulated together (e.g., as a single composition that is applied to the patient's periorbital or eyelid skin).
[0129] In some embodiments, the patient being treated with an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof is further administered chlorpromazine, haloperidol, amisulpiride, levomepromazine, norclozapine, olanzapine, paliperidone, quetiapine, risperidone, sulpiride, toliapride, ziprasidone, thioridazine, aripiprazole, chlorpromazine, clozapine, flupentixol, melperone, perphenazine, pimozide, raclopride, thioridazine, thioxanthene, trifluperazine, hydrochloride, or ziprasidone, or a combination thereof.
[0130] In some embodiments, the patient being treated with the omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof is further administered C-donepezil, donepezil, memantine, rivastigmine, or galantamine, or a combination thereof.
[0131] In some embodiments, the patient being treated with the omega-3 fatty acid, or a pharma- ceutically acceptable ester or salt thereof, is further administered efavirenz, atazanavir, emtricitabine, lamivudine, lopinavir, or tenofovir, or a combination thereof.
[0132] Other active ingredients and excipients In some embodiments, the compound or mixture suitable for topical administration to the periorbital or eyelid is selected from the group consisting of compounds from the following families: CC motif receptor 3 (CCR3) inhibitors, vitamin A and modified forms of vitamin A (such as NCT03845582), complement factor 1q inhibitors, apurinic / apyrimidinic endonuclease 1 / redox effector factor 1 (APE1 / Ref-1) inhibitors, steroids, endothelial cell (EC) specific receptor tyrosine kinase Tie2 agonists (activators), angiopoietin-2 antagonists, retinol binding protein 4 (RBP4) antagonists, complement component 3 (C3) inhibitors, pan-arginylglycylaspartic acid (RGD) integrin antagonists, connexin 43 hemichannel blockers, complement component 5 inhibitors, pan-RGD integrin antagonists, Rho kinase inhibitors, Ref-1 inhibitors, AP endonuclease 1 inhibitors, serine / threonine-protein kinase (SRPK1) inhibitors, CC3 (TIP30 = tat-interacting protein of 30 kDa) inhibitors, complement C1Q inhibitors, complement factor (B and D) inhibitors, C3 convertase inhibitors, C5 convertase inhibitors, inflammasome inhibitors, HtrA1 inhibitors, matrix modulators (such as doxycycline), MASP2 (MBL-associated serine protease 2) blockers, MASP3 (MBL-associated serine protease 3) blockers, antivirals (such as ganciclovir), VEGF receptor (R1, R2, R3) inhibitors, PDGF receptor inhibitors (including imatinib, sorafenib, and sunitinib), prostanoid IP receptor antagonists (e.g., RO3244794), tyrosine kinase inhibitors, PAF (platelet activating factor) receptor inhibitors, and combinations of two or more thereof.
[0133] In some embodiments, pharmaceutical compositions suitable for topical administration to the periorbital or eyelid may include any of the following families of vitamins and antioxidants: Vitamin A (retinol) and modified forms of Vitamin A (e.g., retinoic acid, retinoids such as retinyl acetate, retinyl linoleate, retinyl palmitate and retinyl propionate, carotenoids, β-carotene and NCT03845582); Vitamin B3, including nicotinamide (also known as niacinamide), nicotinic acid (also known as niacin) and nicotinamide riboside; derivatives of Vitamin B3, such as nicotine, nicotinamide adenine dinucleotide (NAD+), NADAH, NADP+ and NADPH; Vitamin C (L-ascorbic acid) and its derivatives, such as sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbyl glucoside, tetrahexyldecyl ascorbate and ethylated L-ascorbic acid.
[0134] In some embodiments, pharmaceutical compositions suitable for topical administration to the periorbital or eyelid may include an antioxidant, which in some embodiments includes lutein, zeaxanthin, riboflavin, and polyunsaturated fatty acids such as docosohexanoic acid (DHA), eicosapentaenoic acid (EPA), vitamin B3, vitamin B6, vitamin B9, vitamin B10, vitamin B20, vitamin B12, vitamin B13, vitamin B14, vitamin B15, vitamin B16, vitamin B17, vitamin B18, vitamin B19, vitamin B20, vitamin B210, vitamin B220, vitamin B23, vitamin B30, vitamin B31, vitamin B32, vitamin B33, vitamin B34, vitamin B35, vitamin B46, vitamin B47, vitamin B48, vitamin B49, vitamin B50, vitamin B51, vitamin B52, vitamin B53, vitamin B54, vitamin B55, vitamin B56, vitamin B57, vitamin B58, vitamin B59, vitamin B60, vitamin B61, vitamin B62, vitamin B63, vitamin B64, vitamin B65, vitamin B66, vitamin B67, vitamin B68, vitamin B69, vitamin B70, vitamin B71, vitamin B72, vitamin B73, vitamin B74, vitamin B75, vitamin B76, vitamin B77, vitamin B78, vitamin B79, vitamin B90, vitamin B91, vitamin B92, vitamin B93, vitamin B94, vitamin B95, vitamin B96, vitamin B97, vitamin B98, vitamin B99, vitamin B106, vitamin B107, vitamin B108, vitamin B109, vitamin B109, vitamin B109, vitamin B110, vitamin B111, vitamin B112, vitamin B113, vitamin B114, vitamin B115, vitamin B116, vitamin B117, vitamin B118, vitamin B119, vitamin B 12 , vitamin C, vitamin E, CoQ10, ghrelin, alpha-lipoic acid, resveratrol, flavonoids, Ginkgo Bilbao extract, ICAPS R®, OFTAN MACULA®, and epigallocatechin-3-gallate.
[0135] In some embodiments, the pharmaceutical composition suitable for topical administration to the periorbital or eyelid may include an additional therapeutic agent. In some embodiments, the additional therapeutic agent is a VEGF antibody, a PDGF antibody, a bFGF antibody, an SDF-1 antibody, an HIF-1 antibody, a PIGF antibody, a VEGF antagonist, a tyrosine kinase inhibitor, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an immunosuppressant, an anticholinergic agent, thalidomide, a prostaglandin receptor antagonist, a neuroprotectant, a neuroregenerative agent, an RNA interference molecule that provides neuroprotection, an RNA interference molecule that promotes neuroregeneration, a small molecule that directly provides neuroprotection and reduces intraocular pressure, an RNA interference molecule that promotes neuroregeneration and reduces intraocular pressure, an RNA interference that provides neuroprotection and reduces intraocular pressure, an antibody that reduces edema, bleeding and angiogenesis, an RNA interference that reduces edema, bleeding and angiogenesis.
[0136] In some embodiments, pharmaceutical compositions suitable for topical administration to the orbital or eyelid may include ligands of the endocannabinoid system, including endogenous and exogenous agonists, antagonists, and inhibitors.Some ligands of the endocannabinoid system, including endogenous and exogenous agonists, antagonists, and inhibitors, are lipophilic and difficult to deliver to the brain, so delivery to the skin of the orbital or eyelid may be the most suitable delivery route to reduce adverse effects and increase the effectiveness of cannabinoid treatment in target tissues, especially the brain / CNS.In some cases, the ligand of the endocannabinoid system may be a salt.In some cases, the ligand of the endocannabinoid system may be polar. Endocannabinoids (endocannabinoids) may include anandamide (AEA), 2-arachidonoylglycerol (2-AG), arachidonic acid (AA), 2-arachidonyl-glycero-ether (noladin, 2-AGE), O-arachidonyl-ethanolamine (virodamine), and N-arachidonoyl-dopamine (NADA). Endocannabinoid molecules may be endogenously synthesized from omega-3 and omega-6 polyunsaturated fatty acids (PUFAs). Ligands of the endocannabinoid system may include naturally occurring cannabis in marijuana, including delta(9)-tetrahydrocannabinol (delta(9)-THC, psychoactive), cannabidiol, and / or dronabinol. Ligands of the endocannabinoid system may include synthetic cannabinoid receptor agonists, including audulemic acid, dronabinol, marinol, nabilone, CP55940, GW-100, HU-210, WIN 55212-2, JWH-015, arachidonyl-2'-chloroethylamide (ACEA, CB1 agonist), dexanabinol (HU-211, CB1 agonist) and / or HU-308 (CB2 agonist). Ligands of the endocannabinoid system may include CB receptor antagonists. Ligands of the endocannabinoid system may include CB1 receptor antagonists, including LH-21, LY320135, SR141716 (rimonabant). Ligands for the endocannabinoid system may include CB2 receptor antagonists, including AM 630 (and partial CB1 agonists) and / or SR145528.Other compounds that act through the endocannabinoid receptor pathway include cannabinoid transport inhibitors such as AM 404 and VCM 707. Other compounds that act through the endocannabinoid receptor pathway include FAAH-resistant transport inhibitors such as AM 1172.
[0137] In one aspect provided herein, a pharmaceutical composition suitable for topical administration to the periorbital region or eyelid may include any pharma- ceutically acceptable excipient. In some embodiments, the pharma-ceutically acceptable excipient includes one or more acids, bases, electrolytes, buffers, solutes, antioxidants, stabilizers, and, optionally, preservatives. In some embodiments, the pharma-ceutically acceptable excipient includes a semi-fluorinated alkane. In some embodiments, the pharma-ceutically acceptable excipient includes perfluorohexyl octane. In some embodiments, the pharma-ceutically acceptable excipient includes perfluorobutyl pentane. In some embodiments, a pharmaceutical composition suitable for topical administration to the periorbital region or eyelid includes an omega-3 fatty acid or a pharma-ceutically acceptable ester or salt thereof and a semi-fluorinated alkane. In some embodiments, a pharmaceutical composition suitable for topical administration to the periorbital region or eyelid includes an omega-3 fatty acid or a pharma-ceutically acceptable ester or salt thereof and perfluorohexyl octane. In some embodiments, a pharmaceutical composition suitable for topical administration to the periorbital or eyelid comprises an omega-3 fatty acid or a pharma- ceutically acceptable ester or salt thereof and perfluorobutylpentane.
[0138] In some embodiments, the composition for periorbital or eyelid delivery comprises an antibody. In some embodiments, the composition has a molecular weight of approximately 1000 kDa. In some embodiments, the composition has a molecular weight of approximately 150 kDa. In some embodiments, the composition has a molecular weight of approximately 7 kDa. In some embodiments, the composition for periorbital or eyelid delivery comprises a double-stranded siRNA. In some embodiments, the composition for periorbital or eyelid delivery comprises a single-stranded siRNA. In some embodiments, the composition comprises a short oligopeptide. In some embodiments, the composition for periorbital or eyelid delivery comprises a short DNA oligonucleotide.
[0139] In some embodiments, the composition for periorbital or eyelid delivery comprises a viral vector. In some embodiments, the composition has a molecular weight of approximately 1000 kDa. In some embodiments, the composition comprises an RNA viral vector. In some embodiments, the composition comprises a DNA viral vector.
[0140] In some embodiments, the short oligopeptide is a sequence of about 1 to about 6 amino acids. In some embodiments, the short oligopeptide is a sequence of about 1 to about 2 amino acids, about 1 to about 3 amino acids, about 1 to about 4 amino acids, about 1 to about 5 amino acids, about 1 to about 6 amino acids, about 2 to about 3 amino acids, about 2 to about 4 amino acids, about 2 to about 5 amino acids, about 2 to about 6 amino acids, about 3 to about 4 amino acids, about 3 to about 5 amino acids, about 3 to about 6 amino acids, about 4 to about 5 amino acids, about 4 to about 6 amino acids, or about 5 to about 6 amino acids. In some embodiments, the short oligopeptide is a sequence of about 1 amino acid, about 2 amino acids, about 3 amino acids, about 4 amino acids, about 5 amino acids, or about 6 amino acids. In some embodiments, the short oligopeptide is a sequence of at least about 1 amino acid, about 2 amino acids, about 3 amino acids, about 4 amino acids, or about 5 amino acids. In some embodiments, the short oligopeptide is a sequence of a maximum of about 2 amino acids, about 3 amino acids, about 4 amino acids, about 5 amino acids, or about 6 amino acids.
[0141] In some embodiments, the composition for periorbital or eyelid delivery comprises liposomes. In some embodiments, the composition comprises nanoparticles. In some embodiments, the liposomes or nanoparticles have an average diameter of about 0.1 μm to about 1 μm. In some embodiments, the liposomes or nanoparticles have an average diameter of about 0.1 μm to about 0.2 μm, about 0.1 μm to about 0.3 μm, about 0.1 μm to about 0.4 μm, about 0.1 μm to about 0.5 μm, about 0.1 μm to about 0.6 μm, about 0.1 μm to about 0.7 μm, about 0.1 μm to about 0.8 μm, about 0.1 μm to about 0.9 μm, about 0.1 μm to about 1 μm, about 0.2 ...5 μm, about 0.1 μm to about 0.6 μm, about 0.1 μm to about 0.7 μm, about 0.1 μm to about 0.8 μm, about 0.1 μm to about 0.9 μm, about .3μm, about 0.2μm to about 0.4μm, about 0.2μm to about 0.5μm, about 0.2μm to about 0.6μm, about 0.2μm to about 0.7μm, about 0.2μm to about 0.8μm, about 0.2μm m ~ about 0.9μm, about 0.2μm - about 1μm, about 0.3μm - about 0.4μm, about 0.3μm - about 0.5μm, about 0.3μm - about 0.6μm, about 0.3μm - about 0.7μm, about 0.3 μm~about 0.8μm, about 0.3μm~about 0.9μm, about 0.3μm~about 1μm, about 0.4μm~about 0.5μm, about 0.4μm~about 0.6μm, about 0.4μm~about 0.7μm, about 0 .4μm~about 0.8μm, about 0.4μm~about 0.9μm, about 0.4μm~about 1μm, about 0.5μm~about 0.6μm, about 0.5μm~about 0.7μm, about 0.5μm~about 0.8μm, about . 0.5 μm to about 0.9 μm, about 0.5 μm to about 1 μm, about 0.6 μm to about 0.7 μm, about 0.6 μm to about 0.8 μm, about 0.6 μm to about 0.9 μm, about 0.6 μm to about 1 μm, about 0.7 μm to about 0.8 μm, about 0.7 μm to about 0.9 μm, about 0.7 μm to about 1 μm, about 0.8 μm to about 0.9 μm, about 0.8 μm to about 1 μm, or about 0.9 μm to about 1 μm. In some embodiments, the average diameter of the liposomes or nanoparticles is about 0.1 μm, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, or about 1 μm. In some embodiments, the average diameter of the liposomes or nanoparticles is at least about 0.1 μm, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, or about 0.9 μm.In some embodiments, the average diameter of the liposomes or nanoparticles is at most about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, or about 1 μm.
[0142] In some embodiments, the composition for periorbital or lid delivery comprises a lipophilic compound. In some embodiments, the composition comprises a non-polar compound. In some embodiments, the composition comprises a bipolar compound. In some embodiments, the composition comprises a zwitterion.
[0143] NIODP for particle delivery Since particles containing macromolecules and drugs can be effectively delivered to the brain and the whole body via periorbital or eyelid administration, NIODP can be used as a particle delivery system. In some embodiments, drug delivery can include nanoparticles. These can be selected from the group including polymeric, lipid-based, liposomal, albumin-bound, inorganic, organic crystal, and virus-based nanoparticles.
[0144] In one aspect, provided herein is a method for delivering one or more particles to the brain, central nervous system, and / or to all parts of the body via administration to the periocular or eyelid skin, and / or by systemic circulation. The particles may include macromolecules such as peptides, proteins, oligonucleotides (RNA or DNA), nucleic acids (RNA and DNA), and viral vectors for gene therapy. The particles may also include low molecular weight drugs. Nanocarriers can be loaded with macromolecules to form nanoparticles such as liposomes, polymeric micelles, lipoplexes, and polyplexes. A wide variety of active agents can be incorporated into nanoparticles, ranging from low molecular weight drug molecules to macromolecules such as proteins and nucleic acids. Liposomes have diverse properties in terms of size, surface charge, and lipid composition. Liposomes have the ability to incorporate almost any drug, regardless of its solubility in water. Lipids can be used to deliver drugs or particles via NIODP. A wide variety of lipids can be used as carriers for preparing liposomes. In some cases, a mixture of stearic acid and Tween 80 can be used. In some cases, a mixture of distearoylphosphatidylcholine, distearoylphosphatidylglycerol, and cholesterol, and / or diplasmenylcholine is used. In some cases, a mixture of distearoylphosphatidylcholine, dimyristoylphosphatidylglycerol, and cholesterol is used. In some cases, a mixture of castor oil, phosphatidylcholine, and polyethylene glycol coupled to distearoylphosphatidylethanolamine is used.
[0145] In some cases, delivery can be promoted or enhanced by increasing periocular or eyelid skin penetration. Skin penetration can be enhanced by including the particles in a material that is easily accepted and absorbed by the skin. In some cases, delivery can be promoted by including the particles in a carrier. The carrier can have the ability to be in a certain area of the body, such as the gastrointestinal tract, the cardiovascular system, the reproductive system, the respiratory system, or the endocrine system. Mixtures of omega-3 fatty acids (DHA alone or with other omega-3 fatty acids of different compositions) and their derivatives can be used as safe carriers for the particles. The particles can be incorporated or complexed with a variety of active agents, from low molecular weight drug molecules to macromolecules.
[0146] In addition to particle delivery systems, NIODPs can be used to deliver foreign bodies to the body. Foreign bodies can include, for example, nanochips or biosensors. In some cases, delivery can be facilitated or enhanced by increasing periocular or eyelid skin penetration. Skin penetration can be enhanced by incorporating the foreign body in a material that is readily accepted and absorbed by the skin. In some cases, delivery can be facilitated by incorporating the foreign body in a carrier. In some cases, the carrier may not release the foreign body until it has had a chance to reach the intended target. The carrier may have high stability and long residence or circulation times after administration. In some cases, this ensures that the foreign body does not proactively degrade or deactivate. The carrier may have the ability to actively or passively deliver the foreign body to a target area. In some cases, the target area is the brain or central nervous system. The target area may be a certain area of the body, such as the gastrointestinal tract, cardiovascular system, reproductive system, respiratory system, or endocrine system. In some cases, the foreign body is covered with a coating specifically selected to mimic the chemistry of the intended target area. This may help promote and integrate the foreign material into the intended area of the body.
[0147] Mixtures of omega-3 fatty acids (DHA alone or with other omega-3 fatty acids of different compositions) and their derivatives can be used as carriers of foreign substances. Mixtures of omega-3 fatty acids (DHA alone or with other omega-3 fatty acids of different compositions) and their derivatives can be used as safe carriers of foreign substances to be delivered via NIODP for CNS delivery or to any other area in the body with or without systemic circulation. In some cases, mixtures of omega-3 fatty acids (DHA alone or with other omega-3 fatty acids of different compositions) can mimic the surface chemistry of individual neurons, which can help promote and integrate foreign substances into the nervous system.
[0148] formulation Compositions for administration to periorbital or eyelid skin In some embodiments, provided herein are compositions suitable for application to the periorbital or eyelid skin area of a subject's eye. In some embodiments, these compositions may be administered by a non-invasive ocular delivery platform (NIODP).
[0149] In some embodiments, the composition is in the form of an aqueous solution, a non-aqueous solution, an oil solution, an oil, a gel, a hydrogel, a lotion, an ointment, a dispersion, an emulsion, a cream, and a suspension. In some embodiments, the composition is in the form of an ointment, a cream, or a lotion. In some embodiments, the composition is in the form of an ointment. In some embodiments, the composition is in the form of an aqueous solution. In some embodiments, the composition is in the form of a non-aqueous solution. In some embodiments, the composition is in the form of an oil solution. In some embodiments, the composition is in the form of an oil. In some embodiments, the composition is in the form of a gel. In some embodiments, the composition is in the form of a hydrogel. In some embodiments, the composition is in the form of a lotion. In some embodiments, the composition is in the form of an ointment. In some embodiments, the composition is in the form of a dispersion. In some embodiments, the composition is in the form of an emulsion. In some embodiments, the composition is in the form of a cream. In some embodiments, the composition is in the form of a suspension.
[0150] In some embodiments, the composition comprises a semi-solid oily base. In some embodiments, the composition comprises a petroleum base, a mineral oil, a polyol, a triglyceride, or any combination thereof. In some embodiments, the composition comprises a petroleum base. In some embodiments, the composition comprises petroleum jelly. In some embodiments, the composition comprises petroleum jelly, a triglyceride, or any combination thereof. In some embodiments, the composition comprises petroleum jelly and a triglyceride. In some embodiments, the composition comprises petroleum jelly, beeswax, or cocoa butter. In some embodiments, the composition comprises beeswax. In some embodiments, the composition comprises cocoa butter.
[0151] In some embodiments, the composition comprises an oil. In some embodiments, the composition comprises an oil or a mixture of oils. In some embodiments, the composition comprises a compound provided herein (e.g., omega-3 fatty acid) mixed with one or more oils. In some embodiments, the composition comprises one or more oils derived from a plant, a plant seed, or a nut. In some embodiments, the plant, plant seed, or nut is soybean, sesame, olive, vegetable, sunflower, or other plant source, or any combination thereof.
[0152] In some embodiments, the composition is mainly oil. In some embodiments, the composition comprises oil in an amount of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, at least about 99.95%, at least about 99.96%, at least about 99.97%, at least about 99.98%, or at least about 99.99% (w / w) of the composition. In some embodiments, the composition consists essentially of oil and active ingredient. In some embodiments, the oil composition consists essentially of active ingredient.
[0153] In some embodiments, the composition comprises an oil in an amount of about 1% to about 100% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition, hi some embodiments, the composition comprises an oil in an amount of up to about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition.
[0154] In some embodiments, the composition comprises a triglyceride. In some embodiments, the triglyceride is a medium or long chain triglyceride. In some embodiments, the triglyceride is derived from a natural source. In some embodiments, the triglyceride is derived from a plant, a plant seed, or a nut. In some embodiments, the plant, plant seed, or nut comprises a soybean, a sesame seed or plant, an olive, a sunflower seed or plant, or a part of another plant or plant source, or any combination thereof.
[0155] In some embodiments, the composition is mainly triglyceride. In some embodiments, the composition comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, at least about 99.95%, at least about 99.96%, at least about 99.97%, at least about 99.98%, or at least about 99.99% (w / w) of the triglyceride of the composition. In some embodiments, the composition consists essentially of triglyceride and active ingredient.
[0156] In some embodiments, the composition comprises triglycerides in an amount of about 1% to about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the composition comprises triglycerides in an amount of about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the composition comprises triglycerides in an amount of at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition. In some embodiments, the composition comprises triglycerides in an amount of up to about 20%, about 40%, about 60%, about 80%, about 90%, or about 100% (w / w) of the composition.
[0157] In some embodiments, the triglyceride is a medium chain triglyceride. In some embodiments, the medium chain triglyceride comprises two or three medium chain fatty acids. In some embodiments, the medium chain triglyceride comprises fatty acids of C6 or higher. In some embodiments, the medium chain triglyceride comprises C6-C12 fatty acids. In some embodiments, the medium chain triglyceride comprises a mixture of C6-C12 fatty acids. In some embodiments, the medium chain triglyceride comprises a fatty acid selected from C6, C8, C10, and C12 fatty acids, or a mixture thereof. In some embodiments, the medium chain triglyceride comprises caproic acid, caprylic acid, capric acid, lauric acid, or any combination thereof. In some embodiments, the medium chain triglyceride comprises caprylic acid, capric acid, or a combination thereof. In some embodiments, the medium chain triglyceride comprises caprylic acid and capric acid. In some embodiments, the medium chain triglycerides comprise caprylic acid and capric acid in a ratio of about 4:1 (w / w), about 4:3 (w / w), about 3:1 (w / w), about 3:2 (w / w), about 1:1 (w / w), about 2:3 (w / w), about 1:3 (w / w), about 3:4 (w / w), or about 1:4 (w / w). In some embodiments, the ratio is about 1:1 (w / w) to about 4:1 (w / w). In some embodiments, the ratio is about 3:2 (w / w). In some embodiments, the medium chain triglycerides comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95% C6-C12 fatty acids compared to other fatty acids (w / w).
[0158] In some embodiments, the composition is predominantly medium chain triglycerides. In some embodiments, the composition comprises medium chain triglycerides in an amount of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, at least about 99.95%, at least about 99.96%, at least about 99.97%, at least about 99.98%, or at least about 99.99% (w / w) of the composition. In some embodiments, the composition consists essentially of medium chain triglycerides and the active ingredient.
[0159] In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1% to about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of up to about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition.
[0160] In some embodiments, the medium chain triglycerides are derived from natural sources. In some embodiments, the medium chain triglycerides are derived from coconut, palm, or palm kernel, or combinations thereof. In some embodiments, the medium chain triglycerides are derived from coconut or palm. In some embodiments, the medium chain triglycerides are oil extracted from coconut or palm endosperm. In some embodiments, the medium chain triglycerides are National Food (NF) grade (NF) or US Pharmacopeia (USP) grade.
[0161] In some embodiments, the composition comprises a mixture of petrolatum and medium chain triglycerides. In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 10:1 (v / v) to about 1:2 (v / v). In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 6:1 (v / v) to about 1:1 (v / v). In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 6:1 (v / v) to about 1:1 (v / v), about 5:1 (v / v) to about 1:1 (v / v), about 4:1 (v / v) to about 1:1 (v / v), about 3:1 (v / v) to about 2:1 (v / v), or about 3:2 (v / v) to about 1:1 (v / v). In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 1:1 (v / v), about 2:1 (v / v), about 3:1 (v / v), about 4:1 (v / v), about 5:1 (v / v), or about 6:1 (v / v). In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 1:1 (v / v). In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 2:1 (v / v). In some embodiments, the ratio of petrolatum to medium chain triglycerides is about 4:1 (v / v).
[0162] In some embodiments, the composition further comprises an emollient, hi some embodiments, the emollient is selected from the group consisting of vegetable oils, mineral oils, essential oils, essential fatty acids, fatty acids, fatty acid esters, and fatty acid alcohols.
[0163] In some embodiments, the composition further comprises a humectant, hi some embodiments, the humectant is selected from the group consisting of propylene glycol, aloe vera, lactic acid, glyceryl triacetate, lithium chloride, polydextrose, quillaja, sodium hexametaphosphate, glycerol, sorbitol, xylitol, maltitol, and castor oil.
[0164] In some embodiments, the composition further comprises a thickening agent, hi some embodiments, the thickening agent is selected from the group consisting of fatty acids, fatty acid esters, and fatty acid alcohols.
[0165] In some embodiments, the composition further comprises a preservative. In some embodiments, the preservative is selected from the group consisting of sodium borate / boric acid, polyhexamethylene biguanide (phmb), parabens (parahydroxybenzoic acid derivatives; phenylmercuric nitrate, benzalkonium chloride, benzalthonium chloride, chlorhexidine, chlorbutanol, methylparaben, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, propylparaben, and thimerosal.
[0166] In some embodiments, the composition is free of preservatives. In some embodiments, the composition is free of benzalkonium chloride.
[0167] In some embodiments, the composition further comprises an antimicrobial agent, hi some embodiments, the antimicrobial agent is selected from the group consisting of basil, oregano, thyme, citrus oils and monoterpenes, sesquiterpenes, and phenylpropanoids.
[0168] In some embodiments, the composition further comprises a penetration enhancer, which in some embodiments is selected from the group consisting of ethanol, isopropyl alcohol, d-hexanol, octanol, docanol, myristyl alcohol, ethyl acetate, oleoyl acetate, isopropyl myristate, azone, carbamide, glyceryl monooleate, octyl salicylate, propylene glycol, dipropylene glycol, 1,2-butylene glycol, oleic acid, N-methyl-2-pyrrolidone, 2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, dimethyl sulfoxide, decyl methyl sulfoxide, sodium lauryl sulfate, Span 80, Tween 80, cineole, eugenol, D-limonene, menthol, menthane, cyclodextrin, hyaluronic acid, and vitamin E.
[0169] In some embodiments, the composition further comprises an odor masking agent.The odor masking agent is particularly suitable for compositions that comprise components derived from animal tissues that may have residual odor (e.g., omega-3 fatty acids derived from fish).In some embodiments, the odor masking agent is an essential oil (e.g., floral, fruit, wood, mint, herb, or other essential oil).
[0170] Composition of omega-3 fatty acids for administration to the external eyelid or periorbital skin In some embodiments, compositions suitable for topical periocular or eyelid skin administration provided herein include an omega-3 fatty acid, an omega-3 acid ethyl ester, an omega-3-carboxylic acid, or a pharma- ceutically acceptable salt thereof, and a pharma-ceutically acceptable excipient. In some embodiments, these compositions may be administered by a non-invasive ocular delivery platform (NIODP).
[0171] In some embodiments, compositions suitable for topical administration to the periorbital or eyelid include an ester, a carboxylic acid, In some embodiments, compositions suitable for topical administration to the periorbital or eyelid provided herein include an omega-3 fatty acid or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.
[0172] In some embodiments, the omega-3 fatty acid is present in the composition in an amount of about 0.01% to about 100% (w / w) of the composition. In some embodiments, the omega-3 fatty acid is present in an amount of about 0.01% to about 50% (w / w) of the composition. In some embodiments, the omega-3 fatty acid is present in an amount of about 1% to about 50% (w / w) of the composition. In some embodiments, the omega-3 fatty acids comprise about 1% to about 5%, about 1% to about 10%, about 1% to about 20%, about 1% to about 30%, about 1% to about 40%, about 1% to about 50%, about 5% to about 10%, about 5% to about 20%, about 5% to about 30%, about 5% to about 40%, about 5% to about 50%, about 5% to about 75%, about 5% to about 100%, about 10% to about 20%, about 10% to about 30%, about 10% to about 40%, about 10% to about 5 ... It is present in an amount of about 75%, about 10% to about 100%, about 20% to about 30%, about 20% to about 40%, about 20% to about 50%, about 20% to about 75%, about 20% to about 100%, about 30% to about 40%, about 30% to about 50%, about 30% to about 75%, about 30% to about 100%, about 40% to about 50%, about 40% to about 75%, about 40% to about 100%, about 50% to about 75%, about 50% to about 100%, or about 75% to about 100% (w / w). In some embodiments, the omega-3 fatty acids are present in an amount of up to about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% (w / w) of the composition. In some embodiments, the omega-3 fatty acids are present in an amount of about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 20% to about 25%, about 20% to about 30%, or about 25% to about 30% (w / w) of the composition.In some embodiments, the omega-3 fatty acids are about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 108, 109, 109, 110, 111, 112, 113, 114, 115, In some embodiments, the omega-3 fatty acid is present in an amount of 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (w / w). In some embodiments, the omega-3 fatty acid is administered alone (e.g., without any vehicle).
[0173] In some embodiments, the composition is configured to deliver an amount of omega-3 fatty acid of about 0.01 mg to about 3000 mg, 0.01 mg to about 1000 mg, about 0.01 mg to about 500 mg, about 0.01 mg to about 200 mg, about 0.01 mg to about 100 mg, about 0.01 mg to about 50 mg, about 0.01 mg to about 20 mg, about 0.01 mg to about 10 mg, about 0.01 mg to about 5 mg, about 0.01 mg to about 2 mg, about 0.01 mg to about 1 mg, about 0.01 mg to about 0.5 mg, or about 0.01 mg to about 0.1 mg. In some embodiments, the composition is configured to deliver an amount of omega-3 fatty acid of about 0.1 mg to about 100 mg. In some embodiments, the composition is configured to deliver omega-3 fatty acids in an amount of about 0.1 mg to about 1 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 20 mg, about 0.1 mg to about 50 mg, about 0.1 mg to about 100 mg, about 1 mg to about 10 mg, about 1 mg to about 20 mg, about 1 mg to about 50 mg, about 1 mg to about 100 mg, about 10 mg to about 20 mg, about 10 mg to about 50 mg, about 10 mg to about 100 mg, about 20 mg to about 50 mg, about 20 mg to about 100 mg, or about 50 mg to about 100 mg. In some embodiments, the composition is configured to deliver omega-3 fatty acids in an amount of about 0.1 mg, about 1 mg, about 10 mg, about 20 mg, about 50 mg, or about 100 mg. In some embodiments, the composition is configured to deliver omega-3 fatty acids in an amount of at least about 0.1 mg, about 1 mg, about 10 mg, about 20 mg, or about 50 mg. In some embodiments, the composition is configured to deliver omega-3 fatty acids in an amount of up to about 1 mg, about 10 mg, about 20 mg, about 50 mg, or about 100 mg.
[0174] In some embodiments, the composition comprises a vehicle for delivering omega-3 fatty acids. In some embodiments, the vehicle comprises an oil. In some embodiments, the vehicle comprises an oil or a mixture of oils. In some embodiments, the vehicle comprises omega-3 fatty acids dissolved in one or more oils. In some embodiments, the oil is from a natural source. In some embodiments, the vehicle comprises one or more oils from plants, plant seeds, or nuts. In some embodiments, the plants, plant seeds, or nuts are soybean, sesame, olive, vegetable, sunflower, or other plant sources, or any combination thereof.
[0175] In some embodiments, the vehicle is an oil. In some embodiments, the composition comprises an oil in an amount of about 1% to about 100% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition. In some embodiments, the composition comprises an oil in an amount of up to about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the oil comprises about 50% to about 99% (w / w) of the composition. In some embodiments, the oil comprises about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 50% to about 99%, about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, about 60% to about 99%, about 70% to about 80%, about 70% to about 90%, about 70% to about 99%, about 80% to about 90%, about 80% to about 99%, or about 90% to about 99% (w / w) of the composition. In some embodiments, the oil comprises about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% (w / w) of the composition.
[0176] In some embodiments, the vehicle comprises a triglyceride. In some embodiments, the triglyceride is a medium or long chain triglyceride. In some embodiments, the triglyceride is derived from a natural source. In some embodiments, the triglyceride is derived from a plant, a plant seed, or a nut. In some embodiments, the plant, plant seed, or nut comprises a soybean, a sesame seed or plant, an olive, a sunflower seed or plant, or a part of another plant or plant source, or any combination thereof.
[0177] In some embodiments, the composition comprises triglycerides in an amount of about 1% to about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the composition comprises triglycerides in an amount of about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the composition comprises triglycerides in an amount of at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition. In some embodiments, the composition comprises triglycerides in an amount of up to about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the triglycerides constitute from about 50% to about 99% (w / w) of the composition. In some embodiments, the triglyceride comprises about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 50% to about 99%, about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, about 60% to about 99%, about 70% to about 80%, about 70% to about 90%, about 70% to about 99%, about 80% to about 90%, about 80% to about 99%, or about 90% to about 99% (w / w) of the composition. In some embodiments, the triglyceride comprises about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% (w / w) of the composition.
[0178] In some embodiments, the triglyceride is a medium chain triglyceride. In some embodiments, the medium chain triglyceride comprises two or three medium chain fatty acids. In some embodiments, the medium chain triglyceride comprises fatty acids of C6 or higher. In some embodiments, the medium chain triglyceride comprises C6-C12 fatty acids. In some embodiments, the medium chain triglyceride comprises a mixture of C6-C12 fatty acids. In some embodiments, the medium chain triglyceride comprises a fatty acid selected from C6, C8, C10, and C12 fatty acids, or a mixture thereof. In some embodiments, the medium chain triglyceride comprises caproic acid, caprylic acid, capric acid, lauric acid, or any combination thereof. In some embodiments, the medium chain triglyceride comprises caprylic acid, capric acid, or a combination thereof. In some embodiments, the medium chain triglyceride comprises caprylic acid and capric acid. In some embodiments, the medium chain triglycerides comprise caprylic acid and capric acid in a ratio of about 4:1 (w / w), about 4:3 (w / w), about 3:1 (w / w), about 3:2 (w / w), about 1:1 (w / w), about 2:3 (w / w), about 1:3 (w / w), about 3:4 (w / w), or about 1:4 (w / w). In some embodiments, the ratio is about 1:1 (w / w) to about 4:1 (w / w). In some embodiments, the ratio is about 3:2 (w / w). In some embodiments, the medium chain triglycerides comprise at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95% C6-C12 fatty acids compared to other fatty acids (w / w).
[0179] In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1% to about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition. In some embodiments, the composition comprises medium chain triglycerides in an amount of up to about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the medium chain triglycerides comprise about 50% to about 99% (w / w) of the composition. In some embodiments, the medium chain triglycerides comprise about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 50% to about 99%, about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, about 60% to about 99%, about 70% to about 80%, about 70% to about 90%, about 70% to about 99%, about 80% to about 90%, about 80% to about 99%, or about 90% to about 99% (w / w) of the composition. In some embodiments, the medium chain triglycerides comprise about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% (w / w) of the composition.
[0180] In some embodiments, the medium chain triglycerides are derived from natural sources. In some embodiments, the medium chain triglycerides are derived from coconut, palm, or palm kernel, or combinations thereof. In some embodiments, the medium chain triglycerides are derived from coconut or palm. In some embodiments, the medium chain triglycerides are oil extracted from coconut or palm endosperm. In some embodiments, the medium chain triglycerides are National Food (NF) grade (NF) or US Pharmacopeia (USP) grade.
[0181] In some embodiments, the vehicle is a fatty acid vehicle. In some embodiments, the fatty acid vehicle is an unsaturated fatty acid. In some embodiments, the fatty acid vehicle is a C14-C22 fatty acid. In some embodiments, the fatty acid vehicle is a C14-C22 unsaturated fatty acid. In some embodiments, the fatty acid vehicle comprises linoleic acid.
[0182] In some embodiments, the fatty acid vehicle comprises about 1% to about 100% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises about 1% to about 20%, about 1% to about 40%, about 1% to about 60%, about 1% to about 80%, about 1% to about 100%, about 20% to about 40%, about 20% to about 60%, about 20% to about 80%, about 20% to about 100%, about 40% to about 60%, about 40% to about 80%, about 40% to about 100%, about 60% to about 80%, about 60% to about 100%, or about 80% to about 100% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises about 1%, about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises at least about 1%, about 20%, about 40%, about 60%, or about 80% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises up to about 20%, about 40%, about 60%, about 80%, or about 100% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises from about 50% to about 99% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 50% to about 99%, about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, about 60% to about 99%, about 70% to about 80%, about 70% to about 90%, about 70% to about 99%, about 80% to about 90%, about 80% to about 99%, or about 90% to about 99% (w / w) of the composition. In some embodiments, the fatty acid vehicle comprises about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% (w / w) of the composition.
[0183] In some embodiments, administering the composition to a patient via NIODP provides a physiologically appropriate amount of omega-3 fatty acid to at least a portion of the brain.In some embodiments, administering the composition to a patient via NIODP provides a physiologically appropriate amount of omega-3 fatty acid to at least a portion of the central nervous system.In some embodiments, administering the composition to a patient via NIODP provides a physiologically appropriate amount of omega-3 fatty acid to be circulated throughout the subject's entire body.
[0184] In some embodiments, administration of the composition to a patient via the NIODP provides a sufficient amount of omega-3 fatty acids in the brain to prevent, treat, or slow / halt disease progression in the brain. In some cases, administration of the composition to a patient via the NIODP provides a therapeutically or physiologically relevant amount of omega-3 fatty acids to at least a portion of the brain. In some cases, following periorbital or lid administration of a topical composition comprising about 100 micrograms to about 500,000 micrograms of omega-3 fatty acids, a brain condition is prevented or treated, symptoms associated therewith are alleviated, or brain deterioration is halted. In some cases, about 100 micrograms to about 500 micrograms, about 100 micrograms to about 1,000 micrograms, about 100 micrograms to about 10,000 micrograms, about 100 micrograms to about 100,000 micrograms, about 100 micrograms to about 500,000 micrograms, about 500 micrograms to about 1,000 micrograms, about 500 micrograms to about 10,000 micrograms, about 500 micrograms to about 100,000 micrograms, about 500 micrograms to about 500,000 micrograms, about 1,000 Following periorbital or lid administration of a topical composition comprising from about 1,000 micrograms to about 100,000 micrograms, from about 1,000 micrograms to about 500,000 micrograms, from about 10,000 micrograms to about 100,000 micrograms, from about 10,000 micrograms to about 500,000 micrograms, or from about 100,000 micrograms to about 500,000 micrograms, a brain condition is prevented or treated, symptoms associated therewith are reduced, or brain deterioration is halted. In some cases, a brain condition is prevented or treated, symptoms associated therewith are reduced, or brain deterioration is halted following periorbital or eyelid administration of a topical composition comprising about 100 micrograms, about 500 micrograms, about 1,000 micrograms, about 10,000 micrograms, about 100,000 micrograms, or about 500,000 micrograms of omega-3 fatty acids.In some cases, a brain condition is prevented or treated, symptoms associated therewith are reduced, or brain deterioration is halted following periorbital or lid administration of a topical composition comprising at least about 100 micrograms, about 500 micrograms, about 1,000 micrograms, about 10,000 micrograms, or about 100,000 micrograms of omega-3 fatty acids. In some cases, a brain condition is prevented or treated, symptoms associated therewith are reduced, or brain deterioration is halted following periorbital or lid administration of a topical composition comprising up to about 500 micrograms, about 1,000 micrograms, about 10,000 micrograms, about 100,000 micrograms, or about 500,000 micrograms of omega-3 fatty acids.
[0185] In some embodiments, administration of the composition to a patient via a non-invasive ocular delivery platform provides a therapeutically or otherwise beneficially relevant amount of omega-3 fatty acids to at least a portion of the central nervous system, hi some embodiments, administration of the composition to a patient via a non-invasive ocular delivery platform provides a therapeutically or otherwise beneficially relevant amount of omega-3 fatty acids circulating throughout the subject's entire body.
[0186] Treatment Provided herein are methods of treating any of the diseases and disorders provided herein with the compounds provided herein. In some embodiments, the compounds are omega-3 fatty acids.
[0187] In some embodiments, the compound is administered to the periorbital or eyelid skin of each patient's eye four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days, or any combination thereof (e.g., variable dosing protocol). In some embodiments, the compound is administered to the periorbital or eyelid skin of each patient's eye once a week, twice a week, three times a week, once every two weeks, or once every three weeks. In some embodiments, the compound is administered to the periorbital or eyelid skin of each patient's eye once a day.
[0188] In some embodiments, the compound is administered twice a day, once a day, once every other day, once every 3 days, once every 4 days, or once every 7 days, or any combination thereof (e.g., variable dosing protocol) to the skin of the periorbital or eyelid of one of the patient's eyes. In some embodiments, the compound is administered once a week, twice a week, three times a week, once a week, once every two weeks, or once every three weeks to the skin of the periorbital or eyelid of one of the patient's eyes. In some embodiments, the compound is administered once a day to the skin of the periorbital or eyelid of one of the patient's eyes.
[0189] In some embodiments, the compound is administered ad libitum to the periorbital or eyelid skin of one or both eyes.
[0190] In some embodiments, the compound is applied to the skin of the periorbital or eyelid using a device. In some embodiments, the device is a dropper, pump, spray, click pen or tube reservoir device. In some embodiments, the compound is topically administered by brush, Q-tip, spatula or fingertip.
[0191] In some embodiments, the device releases a preselected dose evenly onto the patient's periorbital or eyelid skin. In some embodiments, the compound is applied to the periorbital or eyelid skin by a roller device. In some embodiments, the compound is applied to the periorbital or eyelid skin by a Q-tip. In some embodiments, the compound is applied to the periorbital or eyelid skin by a spatula. In some embodiments, the compound is applied to the periorbital or eyelid skin by a fingertip. In some embodiments, a graduated dropper, syringe, click pen, or pipette may be used prior to the application process.
[0192] In some embodiments, the compound is applied to the periorbital or eyelid skin using an eye pad. An eye pad, also known as an eye patch, is a small (possibly sterile) pad large enough to cover the periorbital or eyelid area of the eye and is specifically designed for absorption of a formulation for administration to the periorbital or eyelid. In some embodiments, the eye pad contains a preselected dosage of the active ingredient. The subject can apply the eye pad to the periorbital or eyelid skin for a period of time. The time can depend on the desired dose of the desired active ingredient. In some embodiments, the eye pad can be applied to the patient's periorbital or eyelid skin for 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, or for 1 hour.
[0193] It may be beneficial to use a preservative-free formulation. In some embodiments, the compound is packaged in a disposable container. In some embodiments, the disposable container is a blow-fill-seal capsule. In some embodiments, the disposable container is a soft gel capsule. In some embodiments, the compound is packaged in a multi-use container. In some embodiments, the multi-use container is an airless pump or a dropper bottle. In some embodiments, the packaging is designed to minimize the fishy odor that may be caused by oxidation of omega-3 fatty acids.
[0194] In some embodiments, the compound is administered to the periorbital skin above the upper eyelid, below the lower eyelid, or both above the upper eyelid and below the lower eyelid. In some embodiments, the compound is administered above the upper eyelid. In some embodiments, the compound is administered below the lower eyelid. In some embodiments, the compound is administered both above the upper eyelid and below the lower eyelid.
[0195] In some embodiments, the compound is administered to the upper eyelid, the lower eyelid, or both the upper and lower eyelids. In some embodiments, the compound is administered to the upper eyelid. In some embodiments, the compound is administered to the lower eyelid. In some embodiments, the compound is administered to both the upper and lower eyelids.
[0196] In some embodiments, penetration through periocular or eyelid skin is increased by penetration enhancers, tape stripping, microdermabrasion, solvents, pulsed lasers, and iontophoresis, which have been found to be useful for delivering large molecules, e.g., antibodies, siRNA, in liposomes or nanoparticles.
[0197] In some embodiments, the compound is applied to the eyelid skin using a device. In some embodiments, the device is a dropper, a pump, a spray, a click pen or a tube reservoir device. In some embodiments, the compound is topically administered by a brush, a Q-tip, a spatula or a fingertip.
[0198] In some embodiments, the device releases a preselected dosage evenly onto the patient's eyelid skin. In some embodiments, the compound is applied to the eyelid skin by a roller device. In some embodiments, the compound is applied to the eyelid skin by a Q-tip. In some embodiments, the compound is applied to the eyelid skin by a spatula. In some embodiments, the compound is applied to the eyelid skin by a fingertip. In some embodiments, a graduated dropper, syringe, click pen, or pipette may be used prior to the application process.
[0199] In some embodiments, penetration through the eyelid skin is increased by penetration enhancers, tape stripping, microdermabrasion, solvents, pulsed lasers, and iontophoresis, which have been shown to be useful for delivering macromolecules, such as antibodies, siRNA, within liposomes or nanoparticles (Fukuta et al. (2020) J Control Release 10:323-332).
[0200] In some embodiments, the compounds are administered prophylactically, as an acute intervention, or as needed to achieve a desired therapeutic effect.
[0201] In some cases, the percentage of omega-3 fatty acids delivered to the brain after administration is about 0.04% to about 50% of the administered dose. In some cases, the percentage of omega-3 fatty acids delivered to the brain after administration is about 0.04% to about 0.05%, 0.05% to about 0.1%, about 0.05% to about 0.5%, about 0.05% to about 1%, about 0.05% to about 3%, about 0.05% to about 5%, about 0.05% to about 10%, about 0.05% to about 50%, about 0.1% to about 0.5%, about 0.1% to about 1%, about 0.1% to about 3%, about 0.1% to about 10%, about 0.05 ... About 5%, about 0.1% to about 10%, about 0.1% to about 50%, about 0.5% to about 1%, about 0.5% to about 3%, about 0.5% to about 5%, about 0.5% to about 10%, about 0.5% to about 50%, about 1% to about 3%, about 1% to about 5%, about 1% to about 10%, about 1% to about 50%, about 3% to about 5%, about 3% to about 10%, about 3% to about 50%, about 5% to about 10%, about 5% to about 50%, or about 10% to about 50%. In some cases, the percentage of omega-3 fatty acids delivered to the brain after administration is about 0.04%, 0.05%, about 0.1%, about 0.5%, about 1%, about 3%, about 5%, about 10%, or about 50%. In some cases, the percentage of omega-3 fatty acids delivered to the brain after administration is at least about 0.04%, 0.05%, about 0.1%, about 0.5%, about 1%, about 3%, about 5%, or about 10%. In some cases, the percentage of omega-3 fatty acids delivered to the brain after administration is up to about 0.1%, about 0.5%, about 1%, about 3%, about 5%, about 10%, or about 50% of the administered dose.
[0202] In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of omega-3 fatty acids in the brain of the subject is increased by about 0.5% to about 300%. In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of omega-3 fatty acids in the brain of a subject is increased by about 0.5% to about 1%, about 0.5% to about 5%, about 0.5% to about 25%, about 0.5% to about 50%, about 0.5% to about 100%, about 0.5% to about 300%, about 1% to about 5%, about 1% to about 25%. , about 1% to about 50%, about 1% to about 100%, about 1% to about 300%, about 5% to about 25%, about 5% to about 50%, about 5% to about 100%, about 5% to about 300%, about 25% to about 50%, about 25% to about 100%, about 25% to about 300%, about 50% to about 100%, about 50% to about 300%, or about 100% to about 300%. In some cases, following administration of the omega-3 fatty acid to the periorbital or eyelid skin of the subject, the level of the omega-3 fatty acid in the brain of the subject is increased by about 0.5%, about 1%, about 5%, about 25%, about 50%, about 100%, or about 300%. In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of omega-3 fatty acids in the brain of the subject is increased by at least about 0.5%, about 1%, about 5%, about 25%, about 50%, or about 100%. In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of omega-3 fatty acids in the brain of a subject is increased by up to about 1%, about 5%, about 25%, about 50%, about 100%, or about 300%.
[0203] In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of omega-3 fatty acids in the brain of the subject is about 60 nmol per gram of tissue to about 300 nmol per gram of tissue. In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of omega-3 fatty acids in the brain of a subject is about 60 nmol per gram of tissue to about 75 nmol per gram of tissue, about 60 nmol per gram of tissue to about 90 nmol per gram of tissue, about 60 nmol per gram of tissue to about 100 nmol per gram of tissue, about 60 nmol per gram of tissue to about 110 nmol per gram of tissue, about 60 nmol per gram of tissue to about 120 nmol per gram of tissue, about 60 nmol per gram of tissue to about 130 nmol per gram of tissue, about 60 nmol per gram of tissue to about 140 nmol per gram of tissue, about 60 nmol per gram of tissue to about 150 nmol per gram of tissue, about 60 nmol per gram of tissue to about 160 nmol per gram of tissue, about 60 nmol per gram of tissue to about 170 nmol per gram of tissue, about 60 nmol per gram of tissue to about 180 nmol per gram of tissue, about 60 nmol per gram of tissue to about 190 nmol per gram of tissue, about 60 nmol per gram of tissue to about 200 nmol per gram of tissue, about 60 nmol per gram of tissue to about 210 nmol per gram of tissue, about 60 nmol per gram of tissue to about 220 nmol per gram of tissue, about 60 nmol per gram of tissue to about 250 nmol per gram of tissue, l to about 150 nmol per gram of tissue, about 60 nmol per gram of tissue to about 200 nmol per gram of tissue, about 60 nmol per gram of tissue to about 300 nmol per gram of tissue, about 75 nmol per gram of tissue to about 90 nmol per gram of tissue, about 75 nmol per gram of tissue to about 100 nmol per gram of tissue, about 75 nmol per gram of tissue to about 110 nmol per gram of tissue, about 75 nmol per gram of tissue to about 120 nmol per gram of tissue, about 75 nmol per gram of tissue to about 150 nmol per gram of tissue, about 75 nmol per gram of tissue to about 160 nmol per gram of tissue, about 75 nmol per gram of tissue to about 170 nmol per gram of tissue, about 75 nmol per gram of tissue to about 180 nmol per gram of tissue, about 75 nmol per gram of tissue to about 190 nmol per gram of tissue, about 75 nmol per gram of tissue to about 200 nmol per gram of tissue, about 75 nmol per gram of tissue to about 210 nmol per gram of tissue, about 75 nmol per gram of tissue to about 220 nmol per gram of tissue, about 75 nmol per gram of tissue to about 230 nmol per gram of tissue, about 75 nmol per gram of tissue to about 300 nmol per gram of tissue, about 75 nmol per gram of tissue to about 350 nmol per gram of tissue, about 75 nmol per gram of tissue to about 400 nmol per gram of tissue, about 75 nmol per gram of tissue to about 400 nmol per gram of tissue, about 75 nmol per gram of tissue to about 500 nmol per gram about 150 nmol, about 75 nmol per gram of tissue to about 200 nmol per gram of tissue, about 75 nmol per gram of tissue to about 300 nmol per gram of tissue, about 90 nmol per gram of tissue to about 100 nmol per gram of tissue, about 90 nmol per gram of tissue to about 110 nmol per gram of tissue, about 90 nmol per gram of tissue to about 120 nmol per gram of tissue, about 90 nmol per gram of tissue to about 150 nmol per gram of tissue, about 90 nmol per gram of tissue to about 200 nmol per gram of tissue l, about 90 nmol per gram of tissue to about 300 nmol per gram of tissue, about 100 nmol per gram of tissue to about 110 nmol per gram of tissue, about 100 nmol per gram of tissue to about 120 nmol per gram of tissue, about 100 nmol per gram of tissue to about 150 nmol per gram of tissue, about 100 nmol per gram of tissue to about 200 nmol per gram of tissue, about 100 nmol per gram of tissue to about 300 nmol per gram of tissue, about 110 nmol per gram of tissue to about 120 nmol per gram of tissue,about 110 nmol per gram of tissue to about 150 nmol per gram of tissue, about 110 nmol per gram of tissue to about 200 nmol per gram of tissue, about 110 nmol per gram of tissue to about 300 nmol per gram of tissue, about 120 nmol per gram of tissue to about 150 nmol per gram of tissue, about 120 nmol per gram of tissue to about 200 nmol per gram of tissue, about 120 nmol per gram of tissue to about 300 nmol per gram of tissue, about 150 nmol per gram of tissue to about 200 nmol per gram of tissue, about 150 nmol per gram of tissue to about 300 nmol per gram of tissue, or about 200 nmol per gram of tissue to about 300 nmol per gram of tissue. In some cases, after administration of omega-3 fatty acids to the subject's periorbital or eyelid skin, the level of omega-3 fatty acids in the subject's brain is about 60 nmol per gram of tissue, about 75 nmol per gram of tissue, about 90 nmol per gram of tissue, about 100 nmol per gram of tissue, about 110 nmol per gram of tissue, about 120 nmol per gram of tissue, about 150 nmol per gram of tissue, about 200 nmol per gram of tissue, or about 300 nmol per gram of tissue. In some cases, following administration of omega-3 fatty acids to the subject's periorbital or eyelid skin, the level of omega-3 fatty acids in the subject's brain is at least about 60 nmol per gram of tissue, about 75 nmol per gram of tissue, about 90 nmol per gram of tissue, about 100 nmol per gram of tissue, about 110 nmol per gram of tissue, about 120 nmol per gram of tissue, about 150 nmol per gram of tissue, or about 200 nmol per gram of tissue. In some cases, following administration of omega-3 fatty acids to the subject's periorbital or eyelid skin, the level of omega-3 fatty acids in the subject's brain is up to about 75 nmol / g tissue, about 90 nmol / g tissue, about 100 nmol / g tissue, about 110 nmol / g tissue, about 120 nmol / g tissue, about 150 nmol / g tissue, about 200 nmol / g tissue, or about 300 nmol / g tissue.
[0204] In some cases, after administration of omega-3 fatty acids to the periorbital or eyelid skin of a subject, the level of DHA in the brain of the subject is about 60 nmol per gram of tissue to about 300 nmol per gram of tissue. In some cases, after administration of omega-3 fatty acids to the periorbital or eyelid skin of a subject, the level of DHA in the brain of the subject is about 60 nmol per gram of tissue to about 75 nmol per gram of tissue, about 60 nmol per gram of tissue to about 90 nmol per gram of tissue, about 60 nmol per gram of tissue to about 100 nmol per gram of tissue, about 60 nmol per gram of tissue to about 110 nmol per gram of tissue, about 60 nmol per gram of tissue to about 120 nmol per gram of tissue, about 60 nmol per gram of tissue to about 130 nmol per gram of tissue, about 60 nmol per gram of tissue to about 140 nmol per gram of tissue, about 60 nmol per gram of tissue to about 150 nmol per gram of tissue, about 60 nmol per gram of tissue to about 160 nmol per gram of tissue, about 60 nmol per gram of tissue to about 170 nmol per gram of tissue, about 60 nmol per gram of tissue to about 180 nmol per gram of tissue, about 60 nmol per gram of tissue to about 190 nmol per gram of tissue, about 60 nmol per gram of tissue to about 200 nmol per gram of tissue, about 60 nmol per gram of tissue to about 210 nmol per gram of tissue, about 60 nmol per gram of tissue to about 250 nmol per gram of tissue, about 60 nmol per gram of tissue to about 300 nmol per gram of tissue, about 60 nmol about 150 nmol per gram, about 60 nmol per gram to about 200 nmol per gram, about 60 nmol per gram to about 300 nmol per gram, about 75 nmol per gram to about 90 nmol per gram, about 75 nmol per gram to about 100 nmol per gram, about 75 nmol per gram to about 110 nmol per gram, about 75 nmol per gram to about 120 nmol per gram, about 75 nmol per gram to about 120 nmol per gram 50 nmol, about 75 nmol per gram of tissue to about 200 nmol per gram of tissue, about 75 nmol per gram of tissue to about 300 nmol per gram of tissue, about 90 nmol per gram of tissue to about 100 nmol per gram of tissue, about 90 nmol per gram of tissue to about 110 nmol per gram of tissue, about 90 nmol per gram of tissue to about 120 nmol per gram of tissue, about 90 nmol per gram of tissue to about 150 nmol per gram of tissue, about 90 nmol per gram of tissue to about 200 nmol per gram of tissue , about 90 nmol per gram of tissue to about 300 nmol per gram of tissue, about 100 nmol per gram of tissue to about 110 nmol per gram of tissue, about 100 nmol per gram of tissue to about 120 nmol per gram of tissue, about 100 nmol per gram of tissue to about 150 nmol per gram of tissue, about 100 nmol per gram of tissue to about 200 nmol per gram of tissue, about 100 nmol per gram of tissue to about 300 nmol per gram of tissue, about 110 nmol per gram of tissue to about 120 nmol per gram of tissue,about 110 nmol per gram of tissue to about 150 nmol per gram of tissue, about 110 nmol per gram of tissue to about 200 nmol per gram of tissue, about 110 nmol per gram of tissue to about 300 nmol per gram of tissue, about 120 nmol per gram of tissue to about 150 nmol per gram of tissue, about 120 nmol per gram of tissue to about 200 nmol per gram of tissue, about 120 nmol per gram of tissue to about 300 nmol per gram of tissue, about 150 nmol per gram of tissue to about 200 nmol per gram of tissue, about 150 nmol per gram of tissue to about 300 nmol per gram of tissue, or about 200 nmol per gram of tissue to about 300 nmol per gram of tissue. In some cases, following administration of omega-3 fatty acids to the subject's periorbital or eyelid skin, the level of DHA in the subject's brain is about 60 nmol per gram of tissue, about 75 nmol per gram of tissue, about 90 nmol per gram of tissue, about 100 nmol per gram of tissue, about 110 nmol per gram of tissue, about 120 nmol per gram of tissue, about 150 nmol per gram of tissue, about 200 nmol per gram of tissue, or about 300 nmol per gram of tissue. In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of DHA in the brain of the subject is at least about 60 nmol per gram of tissue, about 75 nmol per gram of tissue, about 90 nmol per gram of tissue, about 100 nmol per gram of tissue, about 110 nmol per gram of tissue, about 120 nmol per gram of tissue, about 150 nmol per gram of tissue, or about 200 nmol per gram of tissue. In some cases, after administration of omega-3 fatty acids to the periocular or eyelid skin of a subject, the level of DHA in the brain of the subject is at most about 75 nmol per gram of tissue, about 90 nmol per gram of tissue, about 100 nmol per gram of tissue, about 110 nmol per gram of tissue, about 120 nmol per gram of tissue, about 150 nmol per gram of tissue, about 200 nmol per gram of tissue, or about 300 nmol per gram of tissue.
[0205] After administering omega-3 fatty acid to the skin of the subject's orbit or eyelid, the target concentration of omega-3 fatty acid in the subject's brain can be maintained for a given period of time after administration.In some cases, the target concentration of omega-3 fatty acid is maintained 1 hour after administration, 3 hours after administration, 5 hours after administration, 10 hours after administration, 12 hours after administration, or 24 hours after administration.In some cases, the target concentration of omega-3 fatty acid is maintained for more than 1 hour after administration, 3 hours after administration, 5 hours after administration, 10 hours after administration, 12 hours after administration, or 24 hours after administration.
[0206] Certain definitions
[0207] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, reference to "the cell" includes reference to one or more cells (or cells) and equivalents thereof known to those of skill in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulas, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about" when referring to a number or numerical range means that the referenced number or numerical range is approximate within experimental variation (or within statistical experimental error), and thus the number or numerical range may vary between 1% and 15% of the stated number or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that certain other embodiments, such as the subject compositions, compositions, methods or processes described herein, may "consist of" or "consist essentially of" the recited features.
[0208] "Prevention" is the act of stopping something from happening or occurring.
[0209] "Progression" is the process of gradually developing or moving to a more advanced state.
[0210] "Treating" or "treatment", as used herein, includes any approach to obtain beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results may include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, reduction in the extent of the disease, stabilization (i.e., not worsening) of the disease state, delay or slowing of disease progression, amelioration, reduction in recurrence of the disease. Treatment can prevent the onset of the disease, reduce the symptoms of the disease, completely or partially eliminate the underlying cause of the disease, shorten the duration of the disease, or a combination of the above.
[0211] "Treat" and "treatment" as used herein may also include prophylactic treatment. The treatment method includes administering a therapeutically effective amount of an active agent to a subject. The administration step may consist of a single administration or may include a series of administrations. The length of the treatment period will depend on various factors, such as the severity of the condition, the age of the patient, the concentration of the active agent, the activity of the composition used for treatment, or a combination thereof. It will also be recognized that the effective dosage of the agent used for treatment or prevention may increase or decrease over the course of a particular treatment or prevention regimen. Changes in dosage may occur and be evident by standard diagnostic assays known in the art. In some cases, chronic administration may be required. For example, the composition is administered to the subject in an amount and for a period sufficient to treat the patient.
[0212] The term "effective amount", "therapeutically effective amount" or "pharmaceutical effective amount" refers to an amount of an active agent effective to treat a disease, such as a brain or CNS disease, a systemic disease, or other disease, including effects ranging from a detectable amount of improvement to a substantial reduction / amelioration of symptoms or a cure of the disease or condition. The result can be a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising an agent as described herein that is required to produce a clinically significant reduction in an ocular disease. For example, for a given aspect (e.g., length of incidence), a therapeutically effective amount indicates at least a 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or 100% increase or decrease. Therapeutic efficacy can also be expressed as a "fold" increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold or more effect over a control. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
[0213] The term "periorbital" refers to the area surrounding the eye socket.
[0214] The term "preorbital" refers to the area in front of the orbit or socket of the eye.
[0215] The term "eyelid" refers to the mobile fold of skin over the eye.
[0216] "OD" refers to the right eye.
[0217] "OS" refers to the left eye.
[0218] "OU" refers to both eyes.
[0219] "Periorbital administration" includes administration to the periorbital skin (as shown in Figure 3), and specifically excludes administration to the upper eyelid, lower eyelid, and eyelid margin.
[0220] The term "lotion" refers to an emulsion liquid dosage form, generally for external application to the skin (US FDA Drug Nomenclature Monograph, No. C-DRG-00201).
[0221] The term "cream" describes an emulsion semisolid dosage form that usually contains >20% water and volatile materials and / or <50% hydrocarbons, waxes or polyols as a vehicle. Creams are more viscous than lotions. This dosage form is generally for external application to the skin (US FDA Drug Nomenclature Monograph, No. C-DRG-00201).
[0222] The term "ointment" describes a semisolid dosage form, usually containing <20% water and volatile materials and / or >50% hydrocarbons, waxes or polyols as a vehicle, which is generally for external application to the skin or mucous membranes (US FDA Drug Nomenclature Monograph, No. C-DRG-00201).
[0223] The term "solution" refers to a clear, homogeneous liquid dosage form containing one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents (US FDA Drug Nomenclature Monograph, No. C-DRG-00201).
[0224] The term "suspension" refers to a heterogeneous mixture containing solid particles large enough to settle.
[0225] The "emulsion" includes, but is not limited to, oil-in-water emulsions, water-in-oil emulsions, -9 The term "microemulsion" refers to the particle size of the emulsion.
[0226] "Formulation" and "composition" are intended to be equivalent and refer to a composition of matter suitable for pharmaceutical use (i.e., to provide a therapeutic effect as well as having acceptable pharmacokinetic and toxicological properties).
[0227] An "emollient" is an agent that softens and soothes the skin.
[0228] A "humectant" is a moisture-absorbing agent that keeps the skin moist.
[0229] A "penetration enhancer" is an agent that improves transdermal drug delivery.
[0230] "Thickening agents" increase the viscosity of the formulation to achieve optimal application properties.
[0231] "Pharmaceutically acceptable" is used equivalently to physiologically acceptable. In certain embodiments, a pharma- ceutically acceptable composition or preparation includes agents for buffering and preservation in storage, and may include buffers and carriers for appropriate delivery, depending on the route of administration.
[0232] The terms "subject", "patient" and "individual" are not intended to be limiting and may generally be interchangeable. That is, an individual described as a "patient" may not necessarily have a given disease, but may simply be seeking medical advice. The term "subject" as used herein includes all members of the animal kingdom that are prone to suffering from the indicated disorder. In some aspects, the subject is a mammal, and in some aspects, the subject is a human.
[0233] The term "combination" refers to separate entities used together to achieve improved or optimal therapeutic benefit and safety. In the simplest case, a combination can be a combination of two fixed dose therapeutic agents administered simultaneously. In this case, the components may be formulated separately or mixed together in a single formulation. However, to achieve satisfactory disease control, the doses of the therapeutic agents and the relative timing of their administration may require some flexibility. For example, in a combination of two therapies, one of the two therapies may be administered first to establish a baseline level of that treatment before the other (second) drug is added. Drug combinations may include administration of drugs by different formulations, methods of administration, and different routes of administration. IP receptors are cell surface proteins that belong to the G protein-coupled receptor superfamily. The major endogenous ligands of IP receptors are prostacyclin (PGI2), prostaglandin E1 (PGE1) and 19(S)-HETE (Woodward D, et al. (2011) Pharmacol Rev 63:471-538; Tunara S et al. (2016) PLOS one 11:0163633).
[0234] Platelet-activating factor (PAF) receptor is also a cell surface protein that belongs to the G protein-coupled receptor superfamily (Ishii S et al. (2002) PGs & Other Lipid Med 68-69:599-609).
[0235] SiRNA refers to the same entity variously described as small interfering RNA, small inhibitory RNA, and short interfering RNA.
[0236] The term "macromolecule," as used herein, refers to a molecule having a size of about 100 to 10,000 angstroms, or a molecule having a molecular weight of more than about 1,500 daltons. The term macromolecule includes, for example, peptides, proteins, nucleic acids (RNA and DNA), oligonucleotides, carbohydrates, lipids / fats, oligonucleotides, and viral vectors used in gene therapy.
[0237] example Example 1: Cynomolgus monkey study with JV-DE1 administered into the periorbital skin of one eye Experiments were conducted to determine the in vivo disposition of 4,5-dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]-1H-imidazol-2-amine (JV-DE1) following topical application to the periorbital skin surrounding the anterior portion of the eyeball. The results are summarized in Table 1. [Table 1]
[0238] A synthetic compound, JV-DE1, 165.4 μg, was applied to the right eye (OD) of cynomolgus monkeys via NIODP. Although monkeys were restrained from rubbing their eyes for 2 h after dosing and closely monitored by the experimenter to prevent cross-contamination of untreated eyes, JV-DE1 was rapidly found in the untreated upper eyelid (733.4 ng / g), retina (5.2 ng / g), and vitreous humor (1.03 ng / mL) as early as 0.5 h after dosing. Low levels of JV-DE1 were detected in the retina, ranging from 5.5 to 45.5 ng / g in treated eyes and 1.4 to 6.3 ng / g in untreated eyes throughout the 3, 6, and 24 h post-dosing time points. The ratio of JV-DE1 in untreated retinas to treated retinas was less than 25.5% at all post-dosing points tested. Lower but substantial JV-DE1 levels were detected in untreated periorbital skin (Cmax 1637.0ng / g) compared to treated periorbital skin (JV-DE1 Cmax 32454.7ng / g). These observations suggest that efflux transporters in the CNS limit JV-DE1 uptake and that the forward TORT pathway (solid black arrow, FIG. 2) appears to provide a rapid unidirectional pathway for JV-DE1 to be rapidly cleared from the CNS to various nearby outlets, such as non-CNS tissues along the forward TORT pathway (including ocular tissue / muscle in untreated eyes, CSF, and / or blood for terminal clearance).
[0239] Example 2: Cynomolgus monkey study of periorbital administered docosahexaenoic acid Experiments were conducted to determine the in vivo disposition of DHA following topical application to the periorbital skin surrounding the anterior portion of the eyeball. The results are summarized in Table 2. [Table 2]
[0240] Docosahexaenoic acid (DHA) is an omega-3 fatty acid and is essential for the formation, function, and protection of neurons. 6775.1 ± 92.5 (mean ± SEM) μg / eye of DHA was applied to the left eye (OS) of cynomolgus monkeys via NIODP. DHA was detected in the upper eyelid (41.1 μg / g) and retina (70.8 μg / g) of untreated ODs as early as 0.5 h after dosing, but this was unlikely to be caused by cross-contamination from eye rubbing, as monkeys were restrained from rubbing their eyes for 2 h after dosing and closely monitored by the experimenter. Throughout the 3, 6, and 24-h time points after dosing, DHA was detected in higher concentrations (5.3 to 41.1 μg / g) in the upper eyelid in untreated eyes, but later than in treated eyes. High concentrations of DHA (35.6 μg / g to 97.3 μg / g) were detected in the untreated retinas, similar to those in the treated retinas. No DHA was detectable in the untreated right corneas or vitreous humor.
[0241] The distribution pattern of DHA in untreated eyes differed from that of treated eyes in three aspects: (1) significantly higher retina / upper eyelid ratio of DHA concentrations: 172%-1678% in untreated eyes and 29%-735% in treated eyes; (2) a constant concentration equilibrium observed between treated and untreated retina, with drug levels being higher in untreated retina: 64%-146% of treated one; (3) a reversal of the retina vs. upper eyelid concentration gradient in treated eyes and an apparent absence of a corneal pathway: the biodistribution gradient of untreated OD was retina >> eyelid >> cornea = vitreous humor = 0. Furthermore, compared to the baseline retina / plasma ratio of 7-fold, there was no significant change in plasma, and the retina / plasma ratio of DHA in untreated eyes was at least 30-fold at each post-dose time point, indicating that uptake of DHA in untreated retina was not derived from blood circulation.
[0242] The fast, high-dose, and constantly equilibrated transretinal biodistribution, as well as the significantly higher retina / upper eyelid ratio of DHA concentrations in untreated eyes, contrasts with the pattern of JV-DE1 between untreated and untreated retinas. DHA may use the TORT and rev-TORT pathways to recirculate between left and right retinal tissues through the optic nerve and exert its physiological functions in the brain. Higher brain concentrations should be achieved by using high-purity (>90%) DHA to deliver approximately 30 mg / eye of DHA to both eyes. In normal healthy subjects, brain gray matter and retinal photoreceptor cells contain 30-40% DHA as phospholipids. In addition to being the major structural element of neuronal membranes, high concentrations of DHA are also found at the intracellular level in synaptic membranes, mitochondria, and microsomes. DHA regulates the fluidity, permeability, and viscosity of synaptic membranes, modulates neurotransmission and gene expression, and activates enzymes, receptors, and ion channels. The presence of fatty acid transporter proteins (FATPs), fatty acid binding proteins (FABPs), and receptors for DHA, as well as its release at synapses, suggest that DHA is not only an essential nutrient for synapse formation and neurotransmission, but also an important cargo in synaptic transmission and is involved in neuronal signaling in the brain.
[0243] Example 3: Endogenous DHA levels in ocular tissues Table 3 shows that the endogenous levels of DHA in monkey ocular tissues are mainly below the lower limit of quantification (LLOQ=0.5 μg / mL) or are negligible. The endogenous levels of DHA are derived from the normal diet and are not due to NIODP administration. This is to confirm that the significantly increased biodistribution of DHA in monkey ocular tissues (including untreated ocular tissues) after administration to the periorbital skin shown in Table 2 is not due to endogenous levels of DHA. [Table 3]
[0244] Example 4: Baseline endogenous levels of DHA, DHA-EE and JV-DE1 in Bama minipigs Table 4 shows endogenous levels of DHA, DHA-EE, and JV-DE1 in Bama minipigs. Endogenous levels were measured in plasma, cerebrospinal fluid, ocular tissues (retina, optic nerve, ocular muscle), and brain. Endogenous levels of DHA are not attributable to NIODP administration of DHA, DHA-EE, or JV-DE1. The baseline data collected in Table 4 was taken from the same lot of pigs from the same vendor as the information collected in Tables 5-7. [Table 4]
[0245] Example 5: Docosahexaenoic acid (DHA) in Bama minipigs after a single administration to the periorbital skin In this example, 6092 μg / eye of DHA was applied to the periorbital skin of the left eye of Bama miniature pigs. As shown in Table 5, DHA was detected in both the left and right halves of the pig's brain 3 hours after administration. 27133.8 ng / g tissue and 24795.8 ng / g tissue were measured in the left and right halves of the brain, respectively. Taking the average of these two figures, the amount of DHA present in the brain 3 hours after administration was 25964.9 ng / g. As shown in Table 4, the endogenous level of DHA in this pig was measured to be 20758 ng / g brain. Thus, this experiment showed that the DHA level in the brain was increased by 5206.8 ng / g or 25% 3 hours after periorbital administration of DHA.
[0246] Considering that the average Bama pig brain weighs approximately 60g, the amount of DHA delivered to the brain can be estimated to be 312,408ng or 312μg. Thus, percentage of administered dose = 312μg delivered to brain / 6092μg administered = 5.1% of the DHA administered locally to pigs via periorbital administration was delivered to the brain. In comparison, only about 0.025% of orally administered DHA is delivered to the brain or CNS. These results indicate that administration of topical DHA formulations to periorbital or eyelid skin provides an efficient platform for delivering DHA to the brain.
[0247] Additionally, higher DHA concentrations were measured in the eye muscles of treated eyes than in untreated eyes, as shown in Table 5. This may be beneficial for NIODP-mediated delivery of DHA to intermediate eye segments to treat related diseases such as intermediate uveitis. [Table 5]
[0248] Example 6: Docosahexaenoic acid ethyl ester (DHA-EE) in Bama minipigs after a single administration to the periorbital skin In this example, 6174 μg / eye of docohexaenoic acid ethyl ester (DHA-EE) was applied to the periorbital skin of the left eye of Bama minipigs. As shown in Table 6, DHA was detected in both the left and right halves of the pig's brain 3 hours after administration. 21099.7 ng / g tissue and 21336.3 ng / g tissue of DHA were measured in the left and right halves of the brain, respectively. At this same time point, DHA-EE was not measured in the brain, but was detectable in the ocular muscle of the treated eye, indicating that DHA-EE is rapidly converted to DHA in the brain after administration. The average amount of DHA present in the brain 3 hours after administration was 21218 ng / g. As shown in Table 4, the endogenous level of DHA in this species of pig was measured to be 20758 ng / g tissue. Thus, this experiment demonstrated that brain DHA levels increased by 460 ng / g or 2.2% from baseline 3 hours after periorbital administration of DHA-EE.
[0249] Considering that the average Bama pig brain weighs approximately 60 g, the amount of DHA delivered to the brain can be estimated to be 27,600 ng or 27.6 μg. Thus, percentage of administered dose = 27.6 μg delivered to brain / 6174 μg administered = 0.45% of the DHA administered locally to pigs via periorbital administration was delivered to the brain. In comparison, only about 0.025% of orally administered DHA is delivered to the brain or CNS. These results indicate that administration of DHA-EE to periorbital or eyelid skin also provides an efficient platform for delivering DHA to the brain. [Table 6]
[0250] Example 7: 4,5-Dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]-1H-imidazol-2-amine (JV-DE1) delivery in Bama minipigs following a single administration to the periorbital skin In this example, 158.45 μg of 4,5-dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]-1H-imidazol-2-amine (JV-DE1) was applied to the periorbital skin of the right eye of a Bama miniature pig. As shown in Table 7, a minimal dose of JV-DE1 was detected in both the left and right halves of the pig's brain 3 hours after administration. 1.37 ng / g tissue and 1.35 ng / g tissue of JV-DE1 were measured in the left and right halves of the brain, respectively. The average amount of JV-DE1 present in the brain 3 hours after administration was 1.36 ng / g. As shown in Table 4, the endogenous levels of JV-DE1 in this pig breed were below the lower limit of quantification.
[0251] Considering that the average Bama pig brain weighs approximately 60 g, the amount of JV-DE1 delivered to the brain can be estimated to be 80.6 ng. Thus, 0.051% of 158.45 μg of JV-DE1 administered to the periorbital skin was delivered to the brain, much lower than the potential delivery of DHA via NIODP. In comparison, only about 0.025% of orally administered DHA is delivered to the brain or CNS. These results indicate that administration to the periorbital or eyelid skin can generally achieve a better percentage of the administered dose in terms of brain delivery than oral administration, even for "non-preferred" compounds such as JV-DE1. [Table 7-1] [Table 7-2]
[0252] Example 8: Distribution of JV-DE1 in New England rabbits after a single administration to the periorbital skin NIODP may be more efficient than topical eye drops for corneal delivery to treat corneal disorders such as dry eye. As shown in Table 1, the Cmax of JV-DE1 is 23929.5ng / g in monkey corneas with 165.4μg / eye delivery via NIODP, whereas the Cmax is only 12124.85ng / g in rabbit corneas when 120μg / eye of JV-DE1 is delivered as eye drops (as shown in Table 8). Thus, NIODP may be used to deliver other compounds (such as DHA) to the cornea to treat corneal disorders such as dry eye. [Table 8]
[0253] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. The present invention is not intended to be limited by the specific examples provided herein. Although the present invention has been described with reference to the foregoing specification, the description and illustration of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions described herein, which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments described herein can be employed in practicing the present disclosure. It is therefore contemplated that the present invention will cover any such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the present invention, and that methods and structures within the scope of these claims and their equivalents are covered thereby.
Claims
1. A method for promoting brain health and preventing or treating disease in a subject, comprising administering a topical pharmaceutical composition comprising an omega-3 fatty acid to the periorbital skin or eyelid of the subject's eye.
2. 2. The method of claim 1, wherein the omega-3 fatty acids are isolated from fish tissue.
3. 10. The method of claim 1, wherein the omega-3 fatty acid is isolated from a plant source.
4. 2. The method of claim 1, wherein the omega-3 fatty acids comprise alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or any combination thereof.
5. 2. The method of claim 1, wherein the omega-3 fatty acid comprises DHA.
6. The method of claim 5 , wherein the topical pharmaceutical composition comprises greater than 50% DHA.
7. The method of claim 5 , wherein the topical pharmaceutical composition comprises greater than 75% DHA.
8. The method of claim 5 , wherein the topical pharmaceutical composition comprises greater than 90% DHA.
9. The method of claim 5 , wherein the topical pharmaceutical composition comprises greater than 95% DHA.
10. The method of claim 5 , wherein the topical pharmaceutical composition comprises greater than 99% DHA.
11. The method of claim 1 , wherein the topical pharmaceutical composition comprises petrolatum.
12. The method of claim 1 , wherein the topical pharmaceutical composition comprises shea butter.
13. The method of claim 1 , wherein the topical pharmaceutical composition comprises lanolin.
14. The method of claim 1 , wherein the topical pharmaceutical composition comprises Vitamin E.
15. 10. The method of claim 1, wherein the topical pharmaceutical composition comprises less than 0.2% Vitamin E.
16. 10. The method of claim 1, wherein the omega-3 fatty acid is administered in an amount of about 0.1 mg to about 3000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 200 mg, or about 0.1 mg to about 100 mg.
17. 10. The method of claim 1, wherein the omega-3 fatty acid is administered in an amount of 5-10 mg per eye.
18. The method of claim 1 , wherein the topical pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution.
19. 10. The method of claim 1, wherein the topical pharmaceutical composition further comprises an emollient, a moisturizer, a thickening agent, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof.
20. The method of claim 1 , wherein the topical pharmaceutical composition further comprises a preservative.
21. The method of claim 1 , wherein the topical pharmaceutical composition is preservative-free.
22. 10. The method of claim 1, wherein the topical pharmaceutical composition is administered with a bottle with a rollerball, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, an eye pad, or a fingertip.
23. 2. The method of claim 1, wherein promoting brain health, preventing or treating disease in a subject comprises treating or preventing addiction, arachnoid cysts, attention deficit hyperactivity disorder, autism, brain injury, brain tumors, catalepsy, encephalitis, epilepsy, meningitis, migraine headaches, multiple sclerosis, myelopathy, Tourette's syndrome, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
24. 13. The method of claim 1, wherein the topical pharmaceutical composition is administered to the subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
25. A method for evaluating the safety profile of an article, comprising administering a topical composition comprising the article to the periorbital skin or eyelid of a subject's eye and measuring the concentration of the article in untreated ocular, brain or central nervous system tissue of the subject, wherein if the concentration of the article exceeds a threshold value, the article is determined to be acceptable for administration to the brain or central nervous system.
26. 26. The method of claim 25, wherein the tissue of the untreated eye comprises retinal tissue.
27. 1. A method for delivering omega-3 fatty acids to the brain of a subject, comprising administering a topical pharmaceutical composition comprising the omega-3 fatty acids to the periorbital skin or eyelid of the eye of the subject, wherein greater than 0.05% of the omega-3 fatty acids administered to the periorbital skin or eyelid of the subject is delivered to the brain of the subject.
28. 28. The method of claim 27, wherein greater than 0.1% of the omega-3 fatty acid administered to the periorbital skin or eyelid of the subject is delivered to the brain of the subject.
29. 28. The method of claim 27, wherein greater than 0.5% of the omega-3 fatty acid administered to the periorbital skin or eyelid of the subject is delivered to the brain of the subject.
30. 28. The method of claim 27, wherein greater than 1.0% of the omega-3 fatty acid administered to the periorbital skin or eyelid of the subject is delivered to the brain of the subject.
31. 28. The method of claim 27, wherein greater than 4.0% of the omega-3 fatty acid administered to the periorbital skin or eyelid of the subject is delivered to the brain of the subject.
32. 28. The method of claim 27, wherein the omega-3 fatty acid is isolated from fish tissue.
33. 28. The method of claim 27, wherein the omega-3 fatty acid is isolated from a plant source.
34. 28. The method of claim 27, wherein the omega-3 fatty acids comprise alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or any combination thereof.
35. 28. The method of claim 27, wherein the omega-3 fatty acid comprises DHA.
36. 36. The method of claim 35, wherein the topical pharmaceutical composition comprises greater than 50% DHA.
37. 36. The method of claim 35, wherein the topical pharmaceutical composition comprises greater than 75% DHA.
38. 36. The method of claim 35, wherein the topical pharmaceutical composition comprises greater than 90% DHA.
39. 36. The method of claim 35, wherein the topical pharmaceutical composition comprises greater than 95% DHA.
40. 36. The method of claim 35, wherein the topical pharmaceutical composition comprises greater than 99% DHA.
41. 28. The method of claim 27, wherein the topical pharmaceutical composition comprises petrolatum.
42. 28. The method of claim 27, wherein the topical pharmaceutical composition comprises shea butter.
43. 28. The method of claim 27, wherein the topical pharmaceutical composition comprises lanolin.
44. 28. The method of claim 27, wherein the topical pharmaceutical composition comprises vitamin E.
45. 28. The method of claim 27, wherein the topical pharmaceutical composition comprises less than 0.2% Vitamin E.
46. 28. The method of claim 27, wherein the omega-3 fatty acid is administered in an amount of about 0.1 mg to about 3000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 200 mg, about 0.1 mg to about 100 mg, or about 0.1 mg to about 30 mg.
47. 28. The method of claim 27, wherein the omega-3 fatty acid is administered in an amount of 5-10 mg per eye.
48. 28. The method of claim 27, wherein the topical pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution.
49. 28. The method of claim 27, wherein the topical pharmaceutical composition further comprises an emollient, a moisturizer, a thickening agent, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof.
50. 28. The method of claim 27, wherein the topical pharmaceutical composition further comprises a preservative.
51. 28. The method of claim 27, wherein the topical pharmaceutical composition is preservative-free.
52. 28. The method of claim 27, wherein the topical pharmaceutical composition is administered with a bottle with a rollerball, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, an eye pad, or a fingertip.
53. 28. The method of claim 27, wherein delivery of the local pharmaceutical composition to the brain of the subject prevents or treats a brain disease in the subject.
54. 54. The method of claim 53, wherein the brain disease comprises addiction, arachnoid cyst, attention deficit hyperactivity disorder, autism, brain injury, brain tumor, catalepsy, encephalitis, epilepsy, meningitis, migraine, multiple sclerosis, myelopathy, Tourette's syndrome, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
55. 28. The method of claim 27, wherein the topical pharmaceutical composition is administered to the subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
56. 28. The method of claim 27, wherein said pharmaceutical composition comprises one or more emollients in an amount of less than 95% (w / w) of said composition.
57. 28. The method of claim 27, wherein the pharmaceutical composition comprises one or more emollients in an amount of less than 50% (w / w) of the composition.
58. 28. The method of claim 27, wherein the pharmaceutical composition comprises the omega-3 fatty acid in an amount of at least 5% (w / w) of the composition.
59. 28. The method of claim 27, wherein the pharmaceutical composition comprises the omega-3 fatty acid in an amount of at least 50% (w / w) of the composition.
60. 28. The method of claim 27, wherein said pharmaceutical composition comprises said omega-3 fatty acid in an amount of at least 95% (w / w) of said composition.
61. 28. The method of claim 27, wherein the pharmaceutical composition further comprises Vitamin E.
62. 62. The method of claim 61, wherein the pharmaceutical composition comprises the vitamin E in an amount less than 0.3% (w / w) of the composition.
63. A pharmaceutical composition formulated for topical administration to the periorbital or eyelid, the pharmaceutical composition comprising an omega-3 fatty acid and one or more emollients.
64. 64. The pharmaceutical composition of claim 63, wherein the omega-3 fatty acid is isolated from fish tissue.
65. 64. The pharmaceutical composition of claim 63, wherein the omega-3 fatty acid is isolated from a plant source.
66. 64. The pharmaceutical composition of claim 63, wherein the omega-3 fatty acid comprises alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or any combination thereof.
67. 64. The pharmaceutical composition of claim 63, wherein the omega-3 fatty acid comprises docosahexaenoic acid (DHA).
68. 68. The pharmaceutical composition of claim 67, comprising more than 50% DHA.
69. 68. The pharmaceutical composition of claim 67, comprising greater than 75% DHA.
70. 68. The pharmaceutical composition of claim 67, comprising greater than 90% DHA.
71. 68. The pharmaceutical composition of claim 67, comprising greater than 95% DHA.
72. 68. The pharmaceutical composition of claim 67, comprising greater than 99% DHA.
73. 64. The pharmaceutical composition of claim 63, wherein the one or more emollients comprises petrolatum.
74. 64. The pharmaceutical composition of claim 63, wherein the one or more emollients comprises shea butter.
75. 64. The pharmaceutical composition of claim 63, wherein the one or more emollients comprises lanolin.
76. 64. The pharmaceutical composition of claim 63, comprising vitamin E.
77. 77. The pharmaceutical composition of claim 76, comprising less than 0.2% vitamin E.
78. 64. The pharmaceutical composition of claim 63, formulated as a cream, emulsion, ointment, or oil solution.
79. 64. The pharmaceutical composition of claim 63, further comprising a humectant, a thickening agent, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof.
80. 64. The pharmaceutical composition of claim 63, further comprising a preservative.
81. 64. The pharmaceutical composition of claim 63, which is preservative-free.
82. 64. The pharmaceutical composition of claim 63, administered via a bottle with a rollerball, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, eye pad, or fingertip.
83. 64. The pharmaceutical composition of claim 63, wherein the topical pharmaceutical composition is administered to the periorbital skin or eyelid of a subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
84. 64. The pharmaceutical composition of claim 63, comprising one or more emollients in an amount of less than 95% (w / w) of the composition.
85. 64. The pharmaceutical composition of claim 63, comprising one or more emollients in an amount of less than 50% (w / w) of the composition.
86. 64. The pharmaceutical composition of claim 63, comprising one or more emollients in an amount of less than 5% (w / w) of the composition.
87. 64. The pharmaceutical composition of claim 63, wherein said omega-3 fatty acid is in an amount of at least 5% (w / w) of said pharmaceutical composition.
88. 64. The pharmaceutical composition of claim 63, wherein said omega-3 fatty acid is in an amount of at least 50% (w / w) of said pharmaceutical composition.
89. 64. The pharmaceutical composition of claim 63, wherein said omega-3 fatty acid is in an amount of at least 95% (w / w) of said pharmaceutical composition.
90. 64. The pharmaceutical composition of claim 63, further comprising vitamin E.
91. 91. The pharmaceutical composition of claim 90, comprising said vitamin E in an amount of less than 0.3% (w / w) of said pharmaceutical composition.
92. 64. The pharmaceutical composition of claim 63, further comprising greater than 3000 μg of said omega-3 fatty acids.
93. 64. The pharmaceutical composition of claim 63, further comprising greater than 5000 μg of said omega-3 fatty acids.
94. 64. The pharmaceutical composition of claim 63, further comprising greater than 6000 μg of said omega-3 fatty acids.
95. 1. A method for delivering omega-3 fatty acids to the brain of a subject, comprising administering a topical pharmaceutical composition comprising the omega-3 fatty acids to the periorbital skin or eyelid of the subject, wherein following administration, the concentration of the omega-3 fatty acids in the brain of the subject exceeds 100 nmol / g tissue.
96. 96. The method of claim 95, wherein after administration, the concentration of the omega-3 fatty acid in the brain of the subject is greater than 110 nmol per gram of tissue.
97. 96. The method of claim 95, wherein the omega-3 fatty acid comprises DHA.
98. 98. The method of claim 97, wherein the topical pharmaceutical composition comprises greater than 50% DHA.
99. 98. The method of claim 97, wherein the topical pharmaceutical composition comprises greater than 75% DHA.
100. 98. The method of claim 97, wherein the topical pharmaceutical composition comprises greater than 90% DHA.
101. 98. The method of claim 97, wherein the topical pharmaceutical composition comprises greater than 95% DHA.
102. 98. The method of claim 97, wherein the topical pharmaceutical composition comprises greater than 99% DHA.
103. 96. The method of claim 95, wherein the topical pharmaceutical composition comprises petrolatum.
104. 96. The method of claim 95, wherein the topical pharmaceutical composition comprises shea butter.
105. 96. The method of claim 95, wherein the topical pharmaceutical composition comprises lanolin.
106. 96. The method of claim 95, wherein the topical pharmaceutical composition comprises Vitamin E.
107. 96. The method of claim 95, wherein the topical pharmaceutical composition comprises less than 0.2% Vitamin E.
108. 96. The method of claim 95, wherein the omega-3 fatty acid is administered in an amount of about 0.1 mg to about 3000 mg, about 0.1 mg to about 1000 mg, about 0.1 mg to about 500 mg, about 0.1 mg to about 200 mg, about 0.1 mg to about 100 mg, or about 0.1 mg to about 30 mg.
109. 96. The method of claim 95, wherein the omega-3 fatty acid is administered in an amount of 5-10 mg per eye.
110. 96. The method of claim 95, wherein the topical pharmaceutical composition is formulated as a cream, emulsion, ointment, or oil solution.
111. 96. The method of claim 95, wherein the topical pharmaceutical composition further comprises an emollient, a moisturizer, a thickening agent, a preservative, a penetration enhancer, an antioxidant, an odor masking agent, or any combination thereof.
112. 96. The method of claim 95, wherein the topical pharmaceutical composition further comprises a preservative.
113. 96. The method of claim 95, wherein the topical pharmaceutical composition is preservative-free.
114. 96. The method of claim 95, wherein the topical pharmaceutical composition is administered with a bottle with a rollerball, a click pen brush, a pump bottle, or an eye dropper bottle and a Q-tip, an eye pad, or a fingertip.
115. 96. The method of claim 95, wherein delivery of the local pharmaceutical composition to the brain of the subject prevents or treats a brain disease in the subject.
116. 116. The method of claim 115, wherein the brain disease comprises addiction, arachnoid cyst, attention deficit hyperactivity disorder, autism, brain injury, brain tumor, catalepsy, encephalitis, epilepsy, meningitis, migraine, multiple sclerosis, myelopathy, Tourette's syndrome, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
117. 96. The method of claim 95, wherein the topical pharmaceutical composition is administered to the subject four times a day, three times a day, twice a day, once a day, once every other day, once every three days, once every four days, or once every seven days.
118. 96. The method of claim 95, wherein said pharmaceutical composition comprises one or more emollients in an amount of less than 95% (w / w) of said composition.
119. 96. The method of claim 95, wherein said pharmaceutical composition comprises one or more emollients in an amount of less than 50% (w / w) of said composition.
120. 96. The method of claim 95, wherein said pharmaceutical composition comprises one or more emollients in an amount of less than 5% (w / w) of said composition.
121. 96. The method of claim 95, wherein said pharmaceutical composition comprises said omega-3 fatty acid in an amount of at least 5% (w / w) of said composition.
122. 96. The method of claim 95, wherein said pharmaceutical composition comprises said omega-3 fatty acid in an amount of at least 50% (w / w) of said composition.
123. 96. The method of claim 95, wherein said pharmaceutical composition comprises said omega-3 fatty acid in an amount of at least 95% (w / w) of said composition.
124. 96. The method of claim 95, wherein the pharmaceutical composition further comprises Vitamin E.
125. 125. The method of claim 124, wherein the pharmaceutical composition comprises the vitamin E in an amount less than 0.3% (w / w) of the composition.
